<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="von-willebrand" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">von-willebrand</book-part-id>
      <title-group>
        <title>von Willebrand Disease</title>
        <alt-title alt-title-type="alt-title">Synonym: von Willebrand Factor Deficiency</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Goodeve</surname>
            <given-names>Anne</given-names>
          </name>
          <degrees>PhD</degrees>
          <email>a.goodeve@shef.ac.uk</email>
          <aff>Professor and Head, Haemostasis Research Group<break/>Sheffield University Faculty of Medicine, Dentistry &#x00026; Health<break/>Principal Clinical Scientist, Sheffield Diagnostic Genetics Service<break/>Sheffield Children's NHS Foundation Trust<break/>Sheffield, United Kingdom</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>James</surname>
            <given-names>Paula</given-names>
          </name>
          <degrees>MD, FRCPC</degrees>
          <email>jamesp@queensu.ca</email>
          <aff>Associate Professor and Hematologist<break/>Queen&#x02019;s University<break/>Kingston, Ontario, Canada</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2009-06-04" date-type="created">
          <day>4</day>
          <month>6</month>
          <year>2009</year>
        </date>
        <date iso-8601-date="2014-07-24" date-type="updated">
          <day>24</day>
          <month>7</month>
          <year>2014</year>
        </date>
        <date iso-8601-date="2010-10-26" date-type="revised">
          <day>26</day>
          <month>10</month>
          <year>2010</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="vhl" document-type="chapter">Von Hippel-Lindau Syndrome</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="was" document-type="chapter">
<italic toggle="yes">WAS</italic>-Related Disorders</related-object>
      <abstract id="von-willebrand.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>von Willebrand disease (VWD), a congenital bleeding disorder caused by deficient or defective plasma von Willebrand factor (VWF), may only become apparent on hemostatic challenge, and bleeding history may become more apparent with increasing age.</p>
          <p>Type 1 VWD (~70% of VWD) typically manifests as mild mucocutaneous bleeding.</p>
          <p>Type 2 VWD accounts for approximately 25% of VWD; the subtypes are:</p>
          <list list-type="bullet">
            <list-item>
              <p>Type 2A, which usually manifests as mild to moderate mucocutaneous bleeding;</p>
            </list-item>
            <list-item>
              <p>Type 2B, which typically manifests as mild to moderate mucocutaneous bleeding that can include thrombocytopenia that worsens in certain circumstances;</p>
            </list-item>
            <list-item>
              <p>Type 2M, which typically manifests as mild-moderate mucocutaneous bleeding;</p>
            </list-item>
            <list-item>
              <p>Type 2N, which can manifest as excessive bleeding with surgery and mimics mild hemophilia A.</p>
            </list-item>
          </list>
          <p>Type 3 VWD (&#x0003c;5% of VWD) manifests with severe mucocutaneous and musculoskeletal bleeding.</p>
          <p>
            <bold>Diagnosis/testing</bold>
          </p>
          <p>The diagnosis of VWD typically requires assays of hemostasis factors specific for VWD and/or molecular genetic testing of <italic toggle="yes">VWF</italic>, the only gene in which pathogenic variants are known to cause VWD. In most cases the diagnosis requires a positive family history.</p>
          <p>
            <bold>Management</bold>
          </p>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Affected individuals benefit from care in a comprehensive bleeding disorders program. Severe bleeding episodes can be prevented or controlled with intravenous infusion of virally inactivated plasma-derived clotting factor concentrates containing both VWF and FVIII; depending on the VWD type, mild bleeding episodes usually respond to intravenous or subcutaneous treatment with desmopressin, a vasopressin analog. Other treatments that can reduce symptoms include fibrinolytic inhibitors and hormones for menorrhagia. Pregnant women with VWD are at increased risk for bleeding complications at or following childbirth.</p>
          <p><italic toggle="yes">Prevention of primary manifestations:</italic> Prophylactic infusions of VWF/FVIII concentrates in individuals with type 3 VWD.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Cautious use of desmopressin (particularly in those age &#x0003c;2 years because of the potential difficulty in restricting fluids in this age group). Vaccination for hepatitis A and B.</p>
          <p><italic toggle="yes">Surveillance:</italic> Follow up in centers experienced in the management of bleeding disorders. For those with type 3 VWD: periodic evaluations by a physiotherapist to monitor joint mobility.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Activities involving a high risk of trauma, particularly head injury; medications with effects on platelet function (ASA, clopidogrel, or NSAIDS); circumcision in infant males should only be considered following consultation with a hematologist.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> If the familial pathogenic variant(s) are known, molecular genetic testing for at-risk relatives to allow early diagnosis and treatment, if needed.</p>
          <p><italic toggle="yes">Pregnancy management</italic>: As VWF levels increase throughout pregnancy, women with baseline VWF and FVIII levels of &#x0003e;30 IU/dL are likely to achieve normal levels by the time of delivery, whereas those with a basal level &#x0003c;20 IU/dL and those with baseline VWF:RCo/VWF:Ag ratio &#x0003c;0.6, are likely to require replacement therapy; desmopressin has been used successfully to cover delivery in women with type 1 VWD; delayed, secondary postpartum bleeding may be a problem.</p>
          <p><italic toggle="yes">Therapies under investigation:</italic> Recombinant VWF, now in clinical trials, is expected to be available soon for use instead of plasma-derived VWF.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Most VWD type 1 and most type 2A, type 2B, and type 2M VWD are inherited in an autosomal dominant (AD) manner. VWD type 2N, type 3 and some type 1 and type 2A are inherited in an autosomal recessive (AR) manner.</p>
          <list list-type="bullet">
            <list-item>
              <p>AD inheritance. Most affected individuals have an affected parent. The proportion of cases caused by <italic toggle="yes">de novo</italic> mutation is unknown. Each child of an individual with AD VWD has a 50% chance of inheriting the pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>AR inheritance. At conception, each sib of an individual with AR VWD has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for family members at risk for AR VWD is possible once the pathogenic variants have been identified in the family.</p>
            </list-item>
          </list>
          <p>Prenatal testing, mostly for type 3 VWD, is possible if the pathogenic variant(s) in the family are known or if linkage analysis using intragenic markers is informative.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="von-willebrand.GeneReview_Scope">
        <title><italic toggle="yes">GeneReview</italic> Scope</title>
        <table-wrap id="von-willebrand.Tc" position="anchor" orientation="portrait">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_von-willebrand.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">von Willebrand Disease: Included Disorders</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_von-willebrand.Tc_1_1_1_1" valign="top" align="left" rowspan="1" colspan="1">
                  <list list-type="bullet">
                    <list-item>
                      <p>Type 1 von Willebrand disease</p>
                    </list-item>
                    <list-item>
                      <p>Type 2A von Willebrand disease</p>
                    </list-item>
                    <list-item>
                      <p>Type 2B von Willebrand disease</p>
                    </list-item>
                    <list-item>
                      <p>Type 2M von Willebrand disease</p>
                    </list-item>
                    <list-item>
                      <p>Type 2N von Willebrand disease</p>
                    </list-item>
                    <list-item>
                      <p>Type 3 von Willebrand disease</p>
                    </list-item>
                  </list>
                </td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>For synonyms and outdated names see <xref ref-type="sec" rid="von-willebrand.Nomenclature">Nomenclature</xref>.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="von-willebrand.Diagnosis">
        <title>Diagnosis</title>
        <sec id="von-willebrand.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>Von Willebrand disease (VWD) is caused by deficient or defective plasma von Willebrand factor (VWF), a large multimeric glycoprotein that plays a pivotal role in primary hemostasis by mediating platelet hemostatic function and stabilizing blood coagulation factor VIII (FVIII).</p>
          <p>The three types of VWD are [<xref ref-type="bibr" rid="von-willebrand.REF.sadler.2006.2103">Sadler et al 2006</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>Type 1, partial quantitative deficiency of essentially normal VWF;</p>
            </list-item>
            <list-item>
              <p>Type 2, qualitative deficiency of defective VWF, which is divided into four subtypes depending on VWF function perturbed: 2A, 2B, 2M, 2N;</p>
            </list-item>
            <list-item>
              <p>Type 3, complete quantitative deficiency of (virtually absent) VWF;</p>
            </list-item>
          </list>
          <p>VWD is suspected in persons with excessive mucocutaneous bleeding including the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Bruising without recognized trauma</p>
            </list-item>
            <list-item>
              <p>Prolonged, recurrent nose bleeds</p>
            </list-item>
            <list-item>
              <p>Bleeding from the gums after brushing or flossing teeth or prolonged bleeding following dental cleaning or dental extractions</p>
            </list-item>
            <list-item>
              <p>Menorrhagia, particularly if occurring since menarche</p>
            </list-item>
            <list-item>
              <p>Prolonged bleeding following surgery, trauma, or childbirth</p>
            </list-item>
          </list>
          <p>The utility of standard clinical assessment tools to score occurrence of symptoms and their severity as part of VWD diagnosis is increasingly recognized [<xref ref-type="bibr" rid="von-willebrand.REF.tosetto.2006.766">Tosetto et al 2006</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.bowman.2008.2062">Bowman et al 2008</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.bowman.2009.1418">Bowman et al 2009</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.rodeghiero.2010.2063">Rodeghiero et al 2010</xref>]. These tools can: determine if there is more bleeding than in the general population; justify the diagnosis of a bleeding disorder; quantify the extent of symptoms, indicating situations requiring clinical intervention; and be used to indicate that a bleeding disorder is unlikely [<xref ref-type="bibr" rid="von-willebrand.REF.tosetto.2011.1143">Tosetto et al 2011</xref>].</p>
          <p>The diagnosis requires assays of hemostasis factors specific for VWD (see <xref ref-type="sec" rid="von-willebrand.Testing">Testing</xref>) and/or molecular genetic testing of <italic toggle="yes">VWF</italic>.</p>
          <p>In addition, the diagnosis requires (in most cases) a positive family history. Note: In mild type 1 VWD, family history may not be positive because of incomplete penetrance and variable expressivity.</p>
        </sec>
        <sec id="von-willebrand.Testing">
          <title>Testing</title>
          <p>
            <bold>Screening tests</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Complete blood count (CBC)</bold> may be normal, but could also show a microcytic anemia (if the individual is iron deficient) or a low platelet count (thrombocytopenia), specifically in type 2B VWD.</p>
            </list-item>
            <list-item>
              <p><bold>Activated partial thromboplastin time (aPTT)</bold> is often normal, but may be prolonged when the factor VIII level is reduced to below 30-40 international units per deciliter (IU/dL), as can be seen in severe type 1 VWD, type 2N VWD, or type 3 VWD. The normal range for factor VIII clotting activity is approximately 50-150 IU/dL.</p>
            </list-item>
            <list-item>
              <p><bold>Prothrombin time (PT)</bold> is normal in VWD.</p>
            </list-item>
            <list-item>
              <p><bold>Other.</bold> Although some laboratories may also include a skin bleeding time and platelet function analysis (PFA closure time) in their evaluation of an individual with suspected VWD, these tests lack sensitivity in persons with mild bleeding disorders.</p>
            </list-item>
          </list>
          <p><bold>Hemostasis factor assays.</bold> The following specific hemostasis factor assays (see <xref ref-type="table" rid="von-willebrand.T.classification_of_vwd_b">Table 1</xref>) should be performed even if the screening tests are normal [<xref ref-type="bibr" rid="von-willebrand.REF.budde.2006.514">Budde et al 2006</xref>]. Note: Normal ranges are determined by individual laboratory and thus are indicative only.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>VWF:RCo.</bold> Functional VWF assay (also called ristocetin cofactor activity assay); that is, ability of VWF to agglutinate platelets, initiated by the antibiotic ristocetin (normal range ~50-200 IU/dL). Several new VWF activity assays are becoming available, but published comparisons between the VWF:RCo assay and these new tests is insufficient to make any recommendation on their use.</p>
            </list-item>
            <list-item>
              <p><bold>VWF:Ag.</bold> Quantity of VWF protein (antigen) in the plasma, measured antigenically using enzyme-linked immunosorbant assay (ELISA) or latex immunoassay (LIA) [<xref ref-type="bibr" rid="von-willebrand.REF.castaman.2010a.227">Castaman et al 2010a</xref>] (normal range ~50-200 IU/dL). A reduced ratio (&#x0003c;0.6) of VWF:RCo/VWF:Ag can indicate loss of high molecular-weight (HMW) multimers.</p>
            </list-item>
            <list-item>
              <p><bold>Factor VIII:C level.</bold> Functional FVIII assay (i.e., activity of FVIII in the coagulation cascade) (normal range~ 50-150 IU/dL)</p>
            </list-item>
          </list>
          <p>If abnormalities in the tests above are identified, specialized coagulation laboratories may also perform the following assays to determine the subtype of VWD:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>VWF multimer analysis.</bold> SDS-agarose electrophoresis used to determine the complement of VWF oligomers in the plasma. Normal plasma contains VWF ranging from dimers to multimers comprising more than 40 dimers. Multimers are classified as low (1-5 dimer), intermediate (6-10 dimer), and high (&#x02265;10 dimers) molecular weight. HMW multimers are decreased or missing in type 2A and often in 2B VWD; intermediate MW may also be lost in type 2A VWD. Abnormalities in satellite (&#x0201c;triplet&#x0201d;) band patterns can give clues as to pathogenesis and help to classify subtypes of type 2 VWD [<xref ref-type="bibr" rid="von-willebrand.REF.budde.2008.762">Budde et al 2008</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Ristocetin-induced platelet agglutination (RIPA).</bold> Ability of VWF to agglutinate platelets at 2-3 concentrations of ristocetin. Agglutination at a low concentration (~0.5-0.7 mg/mL) is abnormal and may indicate type 2B or platelet-type pseudo VWD (PT-VWD) caused by pathogenic variants in <italic toggle="yes">GPIBA</italic> (see <xref ref-type="sec" rid="von-willebrand.Differential_Diagnosis">Differential Diagnosis</xref>), in which enhanced VWF-platelet binding is present.</p>
            </list-item>
            <list-item>
              <p><bold>Binding of FVIII by VWF (VWF:FVIIIB).</bold> Ability of VWF to bind FVIII. Essential in order to identify type 2N VWD.</p>
            </list-item>
            <list-item>
              <p><bold>Collagen binding assay (VWF:CB).</bold> Ability of VWF to bind to collagen (a sub-endothelial matrix component). Used to help define functional VWF discordance (i.e., to help distinguish types 1 and 2 VWD) [<xref ref-type="bibr" rid="von-willebrand.REF.flood.2013.684">Flood et al 2013</xref>]. Collagen I/III mixture is often used, but isolated deficient binding to collagen VI has recently been recognized [<xref ref-type="bibr" rid="von-willebrand.REF.flood.2012.1417">Flood et al 2012</xref>]. Normal range is approximately 50-200 IU/dL. A reduced ratio of VWF:CB/VWF:Ag can indicate loss of HMW multimers.</p>
            </list-item>
          </list>
          <table-wrap id="von-willebrand.T.classification_of_vwd_b" position="anchor" orientation="portrait">
            <label>Table 1. </label>
            <caption>
              <p>Classification of VWD Based on Specific VWF Tests</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">VWD Type</th>
                  <th id="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">VWF:RCo&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">VWF:Ag&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">RCo/Ag</th>
                  <th id="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_5" valign="middle" align="left" scope="col" rowspan="1" colspan="1">FVIII:C IU/dL&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_6" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Multimer Pattern&#x000a0;<sup>2</sup></th>
                  <th id="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_7" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Other</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">1<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Low<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Low<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Equivalent<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">~1.5x VWF:Ag<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">Essentially normal<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_7" valign="middle" align="left" rowspan="1" colspan="1">
                    <hr/>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">2A<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Low<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Low<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">VWF:RCo &#x0003c; VWF:Ag<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Low or normal<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">Abnormal &#x02193; HMW<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_7" valign="middle" align="left" rowspan="1" colspan="1">
                    <hr/>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">2B<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Low<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Low<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">VWF:RCo &#x0003c; VWF:Ag<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Low or normal<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">Often abnormal &#x02193; HMW<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_7" valign="middle" align="left" rowspan="1" colspan="1">&#x02191; RIPA&#x000a0;<sup>3</sup> (&#x02193; platelet count)<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">2M<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Low<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Low<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">VWF:RCo &#x0003c;&#x0003c; VWF:Ag<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Low or normal<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">No loss of HMW<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_7" valign="middle" align="left" rowspan="1" colspan="1">
                    <hr/>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">2N<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Normal/low<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Normal/low<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Equivalent<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;40<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">Normal in most cases<hr/></td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_7" valign="middle" align="left" rowspan="1" colspan="1">&#x02193; VWF:FVIIIB&#x000a0;<sup>4</sup><hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">3</td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Absent</td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Absent</td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;10</td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">Absent</td>
                  <td headers="hd_h_von-willebrand.T.classification_of_vwd_b_1_1_1_7" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="von-willebrand.TF.1.1">
                <label>1. </label>
                <p>Relative to the reference range (approximate values); VWF:RCo (50-200 IU/dL), VWF:Ag (50-200 IU/dL), FVIII:C (50-150 IU/dL)</p>
              </fn>
              <fn id="von-willebrand.TF.1.2">
                <label>2. </label>
                <p>HMW multimers</p>
              </fn>
              <fn id="von-willebrand.TF.1.3">
                <label>3. </label>
                <p>Increased agglutination at low concentrations of ristocetin</p>
              </fn>
              <fn id="von-willebrand.TF.1.4">
                <label>4. </label>
                <p>The ability of VWF to bind and protect FVIII is reduced. VWF and FVIII levels can look exactly like those in males with mild <related-object link-type="booklink" source-id="gene" document-id="hemo-a" document-type="chapter">hemophilia A</related-object> or in symptomatic hemophilia A carrier females.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <sec id="von-willebrand.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Gene.</bold>
<italic toggle="yes">VWF</italic> is the only gene in which pathogenic variants are known to cause VWD.</p>
            <p>Note:</p>
            <list list-type="bullet">
              <list-item>
                <p>The current classification scheme does not restrict VWD to being caused by identifiable pathogenic variants in <italic toggle="yes">VWF</italic>. Evaluation of the entire VWF coding region fails to identify a <italic toggle="yes">VWF</italic> pathogenic variant in some cases of &#x0201c;apparent&#x0201d; VWD. A recent study that used Sanger sequence analysis plus dosage analysis identified pathogenic variants in 94% of individuals with type 3 VWD (n=18) and 94% of individuals with type 2 VWD (n= 32), but detected candidate pathogenic variants in only 68% of those diagnosed with type 1 VWD (n= 28) [<xref ref-type="bibr" rid="von-willebrand.REF.yadegari.2012.662">Yadegari et al 2012</xref>]. Pathogenic variant detection rates in this study closely reflect those of several other studies. Failure to identify a pathogenic variant in <italic toggle="yes">VWF</italic> does not exclude a diagnosis of VWD.</p>
              </list-item>
              <list-item>
                <p>Platelet-type pseudo VWD (PT-VWD) results from pathogenic variants in <italic toggle="yes">GPIBA</italic>, but presents phenotypically like type 2B VWD (see <xref ref-type="sec" rid="von-willebrand.Differential_Diagnosis">Differential Diagnosis</xref>).</p>
              </list-item>
            </list>
            <p><bold>Clinical testing.</bold> Domain structure and exons encoding each VWF domain are shown in <xref ref-type="fig" rid="von-willebrand.F1">Figure 1</xref>.</p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Sequence analysis</bold> of the entire coding region and flanking exon/intron junctions of <italic toggle="yes">VWF</italic> is possible, although it is complicated by gene size, structure, and a partial pseudogene (see <xref ref-type="sec" rid="von-willebrand.Molecular_Genetics">Molecular Genetics</xref>).</p>
              </list-item>
              <list-item>
                <p><bold>Linkage analysis</bold> can be useful in type 3 VWD to facilitate prenatal diagnosis if two pathogenic variants cannot be identified in an affected individual. See <xref ref-type="table" rid="von-willebrand.T.selected_vwf_benign_all">Table 4</xref> for benign allelic variants of <italic toggle="yes">VWF</italic> that are useful for linkage analysis.</p>
              </list-item>
              <list-item>
                <p><bold>Deletion/duplication analysis</bold> of <italic toggle="yes">VWF</italic> using any of a number of methods that detect copy number changes is possible [<xref ref-type="bibr" rid="von-willebrand.REF.yadegari.2011.1083">Yadegari et al 2011</xref>], but the extent of contribution of large deletions or duplications has not been established within VWD patient cohorts and large heterozygous pathogenic variants have likely been previously overlooked. Large deletions currently comprise 7% of pathogenic variant reports in individuals with type 3 VWD in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.vwf.group.shef.ac.uk/index.html">ISTH-SSC VWF Database</ext-link>. Large in-frame deletions have also been reported in type 1 and type 2 VWD [<xref ref-type="bibr" rid="von-willebrand.REF.sutherland.2009.1091">Sutherland et al 2009</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.casari.2010.5371">Casari et al 2010</xref>] and two duplications of one or two exons have also been reported in conference abstracts [<xref ref-type="bibr" rid="von-willebrand.REF.schneppenheim.2011">Schneppenheim et al 2011</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.boisseau.2013">Boisseau et al 2013</xref>].</p>
              </list-item>
              <list-item>
                <p><bold>Gene conversion</bold> events can affect sequences from the 3&#x02019; end of intron 27 into the 5&#x02019; end of exon 28. The pathogenic variants can be recognized through two or more sequential sequence variants from the pseudogene sequence (<italic toggle="yes">VWFP</italic>) replacing those in the coding gene. Conversions of 6-335 bp are most commonly seen and have been reported in VWD types 1, 2B, and 3.</p>
              </list-item>
            </list>
            <p><bold>Type 1 VWD.</bold> Pathogenic variants have been identified in approximately 60%-65% of individuals with type 1 VWD [<xref ref-type="bibr" rid="von-willebrand.REF.cumming.2006.630">Cumming et al 2006</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.goodeve.2007.112">Goodeve et al 2007</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.james.2007a.145">James et al 2007a</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.yadegari.2012.662">Yadegari et al 2012</xref>].</p>
            <list list-type="bullet">
              <list-item>
                <p>Fully penetrant, dominantly inherited missense variants are often identified when VWF:Ag and VWF:RCo levels are lower than 25 IU/dL.</p>
              </list-item>
              <list-item>
                <p>Incompletely penetrant dominantly inherited missense variant, such as p.Tyr1584Cys, are identified in approximately 50% of individuals whose VWF:Ag and VWF:RCo levels are 25-50 IU/dL.</p>
              </list-item>
              <list-item>
                <p>The extent to which incompletely penetrant <italic toggle="yes">VWF</italic> pathogenic variants contribute to bleeding phenotype in individuals with VWF levels above 35 IU/dL is not clear and genetic analysis in such cases may not be easy to interpret [<xref ref-type="bibr" rid="von-willebrand.REF.keeney.2008">Keeney et al 2008</xref>].</p>
              </list-item>
            </list>
            <p>Because approximately 50% of pathogenic variants in type 1 VWD are located between exons 18 and 28, these exons can be analyzed first. However, the entire gene should be sequenced for comprehensive ascertainment of pathogenic variants.</p>
            <p><bold>Type 2 VWD.</bold> Most pathogenic variants seen in types 2A and 2M and all pathogenic missense variants in type 2B are located in exon 28; thus, exon 28 should be examined first when any of these three VWD subtypes is suspected.</p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Type 2A (AD) VWD.</bold> Pathogenic variants are predominantly located in exon 28, affecting the A2 and (to a lesser extent) the A1 domain. The D3 assembly (exons 22 and 25-27) is also a common location of pathogenic variants (AD) [<xref ref-type="bibr" rid="von-willebrand.REF.schneppenheim.2010.4894">Schneppenheim et al 2010</xref>].</p>
              </list-item>
              <list-item>
                <p><bold>Type 2A VWD.</bold> Pathogenic missense variants have also been reported in exons 11-16 (AR), and 52 (AD &#x00026; AR), which should be examined subsequently. Additionally, there are case reports of pathogenic variants in several other exons.</p>
              </list-item>
              <list-item>
                <p><bold>Type 2A (AR) VWD.</bold> Affected individuals are either homozygous for the same missense variant (often seen in consanguineous families) or compound heterozygous for a missense variant and a null allele.</p>
              </list-item>
              <list-item>
                <p><bold>Type 2B (AD) VWD.</bold> Pathogenic missense variants are located in exon 28 in or close to the A1 domain [<xref ref-type="bibr" rid="von-willebrand.REF.federici.2009.526">Federici et al 2009</xref>].</p>
              </list-item>
              <list-item>
                <p><bold>Type 2M (AD) VWD.</bold> Pathogenic variants are predominantly located in exon 28. A small group of variants that impair binding to collagen are located in the A3 domain encoded by exons 29-32 [<xref ref-type="bibr" rid="von-willebrand.REF.keeling.2012.e33">Keeling et al 2012</xref>].</p>
              </list-item>
              <list-item>
                <p><bold>Type 2N (AR) VWD.</bold> Most pathogenic missense variants are located in exons 18-20; a much lower proportion has been reported in exons 17 and 24-25 [<xref ref-type="bibr" rid="von-willebrand.REF.mazurier.2005.350">Mazurier &#x00026; Hilbert 2005</xref>].</p>
                <list list-type="bullet">
                  <list-item>
                    <p>A proportion of individuals are homozygous for a pathogenic missense variant, particularly for <xref ref-type="table" rid="von-willebrand.T.selected_vwf_pathogenic">p.Arg854Gln</xref>, which is present in the heterozygous form in 1% of northern European populations.</p>
                  </list-item>
                  <list-item>
                    <p>Most individuals are compound heterozygotes for a missense variant and a pathogenic variant resulting in a null allele. Less commonly, individuals can be compound heterozygotes for two pathogenic missense variants.</p>
                  </list-item>
                </list>
              </list-item>
            </list>
            <p><bold>Type 3 VWD.</bold> Pathogenic variants associated with type 3 VWD are found throughout the entire coding region of <italic toggle="yes">VWF</italic> (i.e., exons 2-52). Sequence analysis of the entire coding region plus deletion/duplication analysis identifies pathogenic variants in around 90% of type 3 VWD.</p>
            <list list-type="bullet">
              <list-item>
                <p>Twenty percent are missense variants. Locations include the D1 (exons 3-10) and A1-A2 domains (exon 28) (<xref ref-type="fig" rid="von-willebrand.F1">Figure 1</xref>).</p>
              </list-item>
              <list-item>
                <p>Eighty percent are null alleles located throughout <italic toggle="yes">VWF</italic> (see <related-object source-id="gene" document-id="von-willebrand" object-id="von-willebrand.molgen.TA">Table A</related-object>). Null alleles can result from many different types of variant. Null alleles do not produce a functional protein product because a pathogenic variant results in either the complete absence/instability of mRNA or protein or the expression of a non-functional gene product (e.g., a protein that cannot be secreted).</p>
              </list-item>
              <list-item>
                <p>Deletion/duplication (dosage) analysis is possible, but the extent of contribution of large deletions or duplications to VWD has not been well established. Large deletions currently comprise 7% of pathogenic variants reported in individuals with type 3 VWD in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.vwf.group.shef.ac.uk/index.html">ISTH-SSC VWF Database</ext-link>.</p>
              </list-item>
              <list-item>
                <p>Linkage analysis can be a useful alternative to pathogenic variant analyses in families with type 3 VWD seeking prenatal diagnosis if both pathogenic variants cannot be identified.</p>
              </list-item>
            </list>
            <table-wrap id="von-willebrand.T.summary_of_molecular_ge" position="anchor" orientation="portrait">
              <label>Table 2. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in von Willebrand Disease (VWD)</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">VWD Type(s)</th>
                    <th id="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of VWD Attributed to This Type</th>
                    <th id="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_5" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variants Detected`</th>
                    <th id="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_6" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant Detectable by this Method&#x000a0;<sup>2</sup></th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_1" rowspan="10" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">VWF</italic>
                    </td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_2" rowspan="3" valign="middle" align="left" colspan="1">1<hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_3" rowspan="3" valign="middle" align="left" colspan="1">~70%<hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis of entire coding and flanking intronic regions<hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants&#x000a0;<sup>3</sup><hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">60%-65%<hr/></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_4" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion / duplication analysis&#x000a0;<sup>4</sup><hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Partial- and whole-gene deletions/ duplications<hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;5%<hr/></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_4" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis of select exons<hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants&#x000a0;<sup>3</sup> in exons 18-28<hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">~50%<hr/></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">All type 2 forms<hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">~25%&#x000a0;<sup>5</sup><hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis of selected exons<hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants&#x000a0;<sup>3</sup><hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">~90%&#x000a0;<sup>6</sup><hr/></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">2A (AD)<break/>2B<break/>2M<hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">See footnote 2<hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_4" rowspan="3" valign="middle" align="left" colspan="1">Sequence analysis of select exons<hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants&#x000a0;<sup>3</sup> in exon 28<hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">~70%<hr/></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">2A (AR)<hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">See footnote 2<hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1">Sequence variants&#x000a0;<sup>3</sup> in exons 11-16, 22, 25-27 &#x00026; 52<hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">~30% of those with 2A<hr/></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">2N<hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">See footnote 2<hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_5" valign="middle" colspan="1" align="left" rowspan="1">Sequence variants&#x000a0;<sup>3</sup> in exons 18-20<hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">~80%<hr/></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_2" rowspan="2" valign="middle" colspan="1" align="left" scope="row">3<hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1">&#x0003c;5%&#x000a0;<sup>7</sup><hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis of entire coding and flanking intronic regions<hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants&#x000a0;<sup>3</sup><hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">~90%<hr/></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_4" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion / duplication analysis&#x000a0;<sup>4</sup><hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Partial- and whole-gene deletions / duplications<hr/></td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;10%<hr/></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">All types</td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Linkage analysis</td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
                    <td headers="hd_h_von-willebrand.T.summary_of_molecular_ge_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>AD = autosomal dominant inheritance</p>
                </fn>
                <fn>
                  <p>AR = autosomal recessive inheritance</p>
                </fn>
                <fn>
                  <p>NA = not applicable</p>
                </fn>
                <fn id="von-willebrand.TF.2.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="von-willebrand" object-id="von-willebrand.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. See <xref ref-type="sec" rid="von-willebrand.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="von-willebrand.TF.2.2">
                  <label>2. </label>
                  <p>The ability of the test method used to detect a variant that is present in the indicated gene</p>
                </fn>
                <fn id="von-willebrand.TF.2.3">
                  <label>3. </label>
                  <p>Examples of pathogenic variants detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="von-willebrand.TF.2.4">
                  <label>4. </label>
                  <p>Testing that identifies deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
                <fn id="von-willebrand.TF.2.5">
                  <label>5. </label>
                  <p>Type 2 accounts for approximately 25% of all VWD. The relative frequency of the subtypes is 2A&#x0003e;2M&#x0003e;2N&#x0003e;2B in populations of European origin.</p>
                </fn>
                <fn id="von-willebrand.TF.2.6">
                  <label>6. </label>
                  <p>
                    <xref ref-type="bibr" rid="von-willebrand.REF.yadegari.2012.662">Yadegari et al [2012]</xref>
                  </p>
                </fn>
                <fn id="von-willebrand.TF.2.7">
                  <label>7. </label>
                  <p>In populations with frequent consanguineous partnerships, the rate of recessive forms of VWD may be elevated and type 3 VWD comprise a larger proportion of affected individuals.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Test characteristics.</bold> See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nature.com/ejhg/journal/v19/n5/full/ejhg2010222a.html">Clinical Utility Gene Card</ext-link> [<xref ref-type="bibr" rid="von-willebrand.REF.cumming.2011">Cumming et al 2011</xref>] for information on test characteristics including sensitivity and specificity.</p>
          </sec>
        </sec>
        <sec id="von-willebrand.Testing_Strategy">
          <title>Testing Strategy</title>
          <p><bold>To confirm/establish the diagnosis in a proband.</bold> In those individuals with type 2 VWD in whom specific VWD hemostasis factor assays can provide a clear diagnosis, molecular genetic testing may not be warranted.</p>
          <p>Molecular genetic testing for VWD is usually indicated in the following cases:</p>
          <list list-type="bullet">
            <list-item>
              <p>To establish the VWD subtype in those individuals in whom specific VWD hemostasis factor assays suggest VWD, but in whom genetic analysis may provide a more definitive diagnosis</p>
            </list-item>
            <list-item>
              <p>To distinguish between type 2N VWD, mild hemophilia A (males), or a symptomatic carrier of hemophilia A (females), where phenotypic testing remains inconclusive (e.g., VWF:FVIIIB assay is unavailable or inconclusive)</p>
            </list-item>
            <list-item>
              <p>To distinguish between type 2B VWD and PT-VWD, as treatment may differ for these two disorders.</p>
            </list-item>
            <list-item>
              <p>For families with type 3 VWD requesting prenatal diagnosis</p>
            </list-item>
            <list-item>
              <p>To determine inheritance pattern and thus risk to family members, when this is unclear from pedigree analysis</p>
            </list-item>
          </list>
          <p>A guideline on VWD genetic testing has been published by the UK Haemophilia Centre Doctors&#x02019; Organisation [<xref ref-type="bibr" rid="von-willebrand.REF.keeney.2008">Keeney et al 2008</xref>]</p>
        </sec>
      </sec>
      <sec id="von-willebrand.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="von-willebrand.Clinical_Description">
          <title>Clinical Description</title>
          <p>von Willebrand disease (VWD) is a congenital bleeding disorder; however, symptoms may only become apparent on hemostatic challenge and bleeding history may become more apparent with increasing age. Thus, it may take some time before a bleeding history becomes apparent.</p>
          <p>Bleeding history also depends on disease severity; type 3 VWD is often apparent early in life, whereas mild type 1 VWD may not be diagnosed until midlife, despite a history of bleeding episodes.</p>
          <p>Individuals with VWD primarily manifest excessive mucocutaneous bleeding (bruising, epistaxis, menorrhagia, etc.) and do not tend to experience musculoskeletal bleeding unless the FVIII:C level is lower than 10 IU/dL, as can be seen in type 2N or type 3 VWD.</p>
          <p><bold>Type 1 VWD</bold> accounts for approximately 70% of all VWD in populations with infrequent consanguineous partnerships. It typically manifests as mild mucocutaneous bleeding; however, symptoms can be more severe when VWF levels are lower than 15 IU/dL. Epistaxis and bruising are common symptoms among children. Menorrhagia is the most common finding in women of reproductive age [<xref ref-type="bibr" rid="von-willebrand.REF.james.2006.546">James &#x00026; Lillicrap 2006</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.kadir.2006.605">Kadir &#x00026; Chi 2006</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.tosetto.2006.766">Tosetto et al 2006</xref>].</p>
          <p><bold>Type 2 VWD</bold> accounts for approximately 25% of all VWD. The relative frequency of the subtypes is 2A&#x0003e;2M&#x0003e;2N&#x0003e;2B in European populations.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Type 2A VWD.</bold> Individuals with type 2A VWD usually present with mild to moderate mucocutaneous bleeding.</p>
            </list-item>
            <list-item>
              <p><bold>Type 2B VWD.</bold> Individuals typically present with mild-moderate mucocutaneous bleeding. Thrombocytopenia may be present. A hallmark of type 2B VWD is a worsening of thrombocytopenia during stressful situations, such as severe infection or during surgery or pregnancy, or if treated with desmopressin.</p>
            </list-item>
            <list-item>
              <p><bold>Type 2M VWD.</bold> Individuals typically present with mild-moderate mucocutaneous bleeding symptoms, but bleeding episodes can be severe, particularly in the presence of very low or absent VWF:RCo [<xref ref-type="bibr" rid="von-willebrand.REF.castaman.2012.632">Castaman et al 2012</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Type 2N VWD.</bold> Symptoms are essentially the same as those seen in mild hemophilia A and include excessive bleeding at the time of surgery or procedures as both disorders result from reduced FVIII:C.</p>
            </list-item>
          </list>
          <p><bold>Type 3 VWD</bold> accounts for less than 5% of VWD, apart from in areas where consanguineous partnerships are common. It manifests with severe bleeding including both excessive mucocutaneous bleeding and musculoskeletal bleeding [<xref ref-type="bibr" rid="von-willebrand.REF.metjian.2009.918">Metjian et al 2009</xref>].</p>
        </sec>
        <sec id="von-willebrand.GenotypePhenotype_Correla">
          <title>Genotype-Phenotype Correlations</title>
          <p>In general, there is an inverse relationship between the VWF level and the severity of bleeding [<xref ref-type="bibr" rid="von-willebrand.REF.tosetto.2006.766">Tosetto et al 2006</xref>]. Bleeding scores (BS) have been documented in several cohort studies and give an indication of the range of bleeding severity associated with different VWD types and with specific pathogenic variants:</p>
          <table-wrap id="von-willebrand.T.bleeding_scores_by_vwd" position="anchor" orientation="portrait">
            <label>Table 3. </label>
            <caption>
              <p>Bleeding Scores by VWD Type</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Patient Group</th>
                  <th id="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Study</th>
                  <th id="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Number of Patients</th>
                  <th id="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">BS Median</th>
                  <th id="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_5" valign="middle" align="left" scope="col" rowspan="1" colspan="1">BS Range</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Type 1<hr/></td>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="von-willebrand.REF.goodeve.2007.112">Goodeve et al [2007]</xref>
                    <hr/>
                  </td>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">150<hr/></td>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">9<hr/></td>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">-1-24<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Type 2A<hr/></td>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="von-willebrand.REF.castaman.2012.632">Castaman et al [2012]</xref>
                    <hr/>
                  </td>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">46<hr/></td>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">11<hr/></td>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">6-16<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Type 2B<hr/></td>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="von-willebrand.REF.federici.2009.526">Federici et al [2009]</xref>
                    <hr/>
                  </td>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">40<hr/></td>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">5<hr/></td>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">4-24<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Type 2M<hr/></td>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="von-willebrand.REF.castaman.2012.632">Castaman et al [2012]</xref>
                    <hr/>
                  </td>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">61<hr/></td>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">7<hr/></td>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">4-28<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Type 3<hr/></td>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="von-willebrand.REF.solimando.2012.870">Solimando et al [2012]</xref>
                    <hr/>
                  </td>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">9<hr/></td>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">15<hr/></td>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">6-26<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Type 3</td>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="von-willebrand.REF.bowman.2013.512">Bowman et al [2013]</xref>
                  </td>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">42</td>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">13</td>
                  <td headers="hd_h_von-willebrand.T.bleeding_scores_by_vwd_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">3-30</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>The higher the bleeding score, the greater the bleeding severity</p>
              </fn>
              <fn>
                <p>Note: Although the studies above have all used similar bleeding assessment tools, slight variations in the tools and their application may have contributed to differences in bleeding scores.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Type 2N VWD.</bold> Pathogenic missense variants reduce the ability of VWF to bind and protect FVIII. VWF and FVIII levels can look exactly like those in males with mild hemophilia A or in symptomatic hemophilia A carrier females.</p>
          <p><bold>ABO blood group.</bold> Blood group contributes approximately 25% of the variance in plasma VWF level; ABO glycosylation of VWF influences its rate of clearance [<xref ref-type="bibr" rid="von-willebrand.REF.jenkins.2006.1836">Jenkins &#x00026; O'Donnell 2006</xref>]. Individuals with non-O blood groups have higher VWF levels than those with O blood group; those with group AB have the highest levels. ABO blood group appears to be an important contributor to penetrance and reduced VWF level in type 1 VWD [<xref ref-type="bibr" rid="von-willebrand.REF.goodeve.2007.112">Goodeve et al 2007</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.james.2007a.145">James et al 2007a</xref>], as has been observed with the common pathogenic variant <xref ref-type="table" rid="von-willebrand.T.selected_vwf_benign_all">p.Tyr1584Cys</xref> [<xref ref-type="bibr" rid="von-willebrand.REF.o_brien.2003.549">O'Brien et al 2003</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.davies.2007.2840">Davies et al 2007</xref>].</p>
        </sec>
        <sec id="von-willebrand.Penetrance">
          <title>Penetrance</title>
          <p><bold>VWD type 1 (AD).</bold> Pathogenic variants resulting in plasma VWF levels lower than 25 IU/dL are mostly fully penetrant. Those resulting in higher VWF levels are often incompletely penetrant.</p>
          <p>Pathogenic variants causal for other AD types, 2A, 2B, and 2M are often fully penetrant.</p>
        </sec>
        <sec id="von-willebrand.Nomenclature">
          <title>Nomenclature</title>
          <p>Changes in nomenclature:</p>
          <list list-type="bullet">
            <list-item>
              <p>von Willebrand's disease has been replaced by von Willebrand disease.</p>
            </list-item>
            <list-item>
              <p>vWF has been replaced by VWF.</p>
            </list-item>
            <list-item>
              <p>vWD has been replaced by VWD.</p>
            </list-item>
            <list-item>
              <p>RiCof (ristocetin cofactor activity) has been replaced by VWF:RCo [<xref ref-type="bibr" rid="von-willebrand.REF.mazurier.2001.712">Mazurier &#x00026; Rodeghiero 2001</xref>]; see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.vwf.group.shef.ac.uk/nomenclature.html">ISTH VWF Web site</ext-link> for nomenclature.</p>
            </list-item>
            <list-item>
              <p>FVIII RAg (FVIII related antigen) has been replaced by VWF:Ag.</p>
            </list-item>
            <list-item>
              <p>Platelet-type pseudo von Willebrand disease (PT-VWD), also called pseudo-VWD, is caused by pathogenic variants in <italic toggle="yes">GP1BA</italic> and, thus, is not a form of VWD (see <xref ref-type="sec" rid="von-willebrand.Differential_Diagnosis">Differential Diagnosis</xref>).</p>
            </list-item>
            <list-item>
              <p>Acquired von Willebrand syndrome (AVWS), previously known as acquired VWD, is the preferred terminology for defects in VWF concentration, structure, or function that are neither inherited nor reflective of pathogenic variants in <italic toggle="yes">VWF</italic>, but arise as consequences of other medical conditions (see brief discussion of AVWS under <xref ref-type="sec" rid="von-willebrand.Differential_Diagnosis">Differential Diagnosis</xref>).</p>
            </list-item>
          </list>
        </sec>
        <sec id="von-willebrand.Prevalence">
          <title>Prevalence</title>
          <p>VWD affects 0.1% to 1% of the population; one in 10,000 seek tertiary care referral.</p>
          <p>VWD type 3 affects 0.5 to six per million population, increasing with the rate of consanguinity.</p>
        </sec>
      </sec>
      <sec id="von-willebrand.Genetically_Related_Allel">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with pathogenic variants in <italic toggle="yes">VWF</italic>.</p>
      </sec>
      <sec id="von-willebrand.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Two disorders can be difficult to distinguish phenotypically from von Willebrand disease (VWD):</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Mild</bold>
<related-object link-type="booklink" source-id="gene" document-id="hemo-a" document-type="chapter"><bold>hemophilia A</bold></related-object><bold>,</bold> caused by pathogenic variants in <italic toggle="yes">F8</italic>, resembles <bold>type 2N VWD</bold> in that reduced levels of FVIII:C (~5-40 IU/dL) and normal-to-borderline-low levels of VWF can be seen in both disorders. The VWF:FVIIIB test, which determines the ability of VWF to bind FVIII, can be used to distinguish between the two disorders [<xref ref-type="bibr" rid="von-willebrand.REF.casonato.2007.194">Casonato et al 2007</xref>] and a commercial assay is now available [<xref ref-type="bibr" rid="von-willebrand.REF.veyradier.2011.944">Veyradier et al 2011</xref>]; however, its availability may be limited. Alternatively, molecular genetic testing can be used to differentiate the two disorders. In families with reduced FVIII:C, an X-linked pattern of inheritance can help identify those with mild hemophilia A. When family history is uninformative, sequence analysis of <italic toggle="yes">F8</italic> should be performed first, even in symptomatic females who are simplex cases (i.e., a single occurrence in a family), because an <italic toggle="yes">F8</italic> pathogenic variant plus skewed X-chromosome inactivation are often responsible for symptoms. In these cases, <italic toggle="yes">F8</italic> intrachromosomal inversions should be sought and DNA sequence analysis or scanning of <italic toggle="yes">F8</italic> exons 1-26 performed. In females, dosage analysis of <italic toggle="yes">F8</italic> can also be used to identify heterozygous partial/complete gene deletions/duplications. Pathogenic variants are detected in more than 50% of cases investigated for &#x0201c;possible 2N VWD or hemophilia A.&#x0201d; When <italic toggle="yes">F8</italic> pathogenic variants are absent, screening of <italic toggle="yes">VWF</italic> exons should follow.</p>
          </list-item>
          <list-item>
            <p><bold>PT-VWD (also called pseudo VWD)</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/177820">177820</ext-link>), caused by pathogenic variants in <italic toggle="yes">GP1BA</italic>, may be difficult to distinguish from <bold>type 2B VWD</bold>. The two disorders can be distinguished by mixing patient/control plasma and platelets to determine which component is defective [<xref ref-type="bibr" rid="von-willebrand.REF.favaloro.2007.623">Favaloro et al 2007</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.favaloro.2008.113">Favaloro 2008</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.franchini.2008.91">Franchini et al 2008</xref>]. When pathogenic variants are absent from exon 28 of <italic toggle="yes">VWF</italic>, pathogenic variants in exon 2 of <italic toggle="yes">GP1BA</italic> may be identified. To date, pathogenic missense variants reported are between GpIb&#x003b1; amino acids Trp246 and Met255 plus a 27-bp in-frame deletion Pro449_Ser457del (1345_1371del27) [<xref ref-type="bibr" rid="von-willebrand.REF.othman.2005.4330">Othman et al 2005</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.hamilton.2011.501">Hamilton et al 2011</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.woods.2014.151">Woods et al 2014</xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.pt-vwd.org/">PT-VWD Registry</ext-link>] (per standard naming conventions of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org">Human Genome Variation Society</ext-link>; reference sequences <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000164.4">NP_000164.4</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000173.4">NM_000173.4</ext-link>). PT-VWD is probably underdiagnosed. Misdiagnosis of the disorder may result in ineffective treatment. VWF concentrate is needed to correct the reduced VWF level, but platelet transfusion may also be required if there is significant thrombocytopenia. The half-life of replaced VWF is reduced as a result of binding to the abnormal GpIb&#x003b1;, necessitating more frequent adminstration of VWF concentrate than in VWD. Molecular genetic testing of <italic toggle="yes">GP1BA</italic> may identify missense or in-frame variants in up to 15% of persons diagnosed with 2B VWD [<xref ref-type="bibr" rid="von-willebrand.REF.hamilton.2011.501">Hamilton et al 2011</xref>].</p>
          </list-item>
        </list>
        <p><bold>Acquired von Willebrand syndrome (AVWS)</bold> is a mild-moderate bleeding disorder that can occur in a variety of conditions [<xref ref-type="bibr" rid="von-willebrand.REF.federici.2006.s48">Federici 2006</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.nichols.2008">Nichols et al 2008</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.sucker.2009.177">Sucker et al 2009</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.federici.2013.191">Federici et al 2013</xref>] but is not caused by mutation of <italic toggle="yes">VWF</italic>. It is most often seen in persons older than age 40 years with no prior bleeding history. AVWS has diverse pathology and may result from:</p>
        <list list-type="bullet">
          <list-item>
            <p>Lymphoproliferative or plasma cell proliferative disorders, paraproteinemias (monoclonal gammopathy of unknown significance [MGUS]), multiple myeloma, and Waldenstrom macroglobulinemia. Antibodies against VWF have been detected in some of these cases.</p>
          </list-item>
          <list-item>
            <p>Autoimmune disorders including systemic lupus erythrematosus (SLE), scleroderma, and antiphospholipid antibody syndrome</p>
          </list-item>
          <list-item>
            <p>Shear-induced VWF conformational changes leading to increased VWF proteolysis (e.g., aortic valve stenosis, ventricular septal defect)</p>
          </list-item>
          <list-item>
            <p>Markedly increased blood platelet count (e.g., essential thrombocythemia or other myeloproliferative disorders)</p>
          </list-item>
          <list-item>
            <p>Removal of VWF from circulation by aberrant binding to tumor cells (e.g., Wilm&#x02019;s tumor or certain lymphoproliferative disorders)</p>
          </list-item>
          <list-item>
            <p>Decreased VWF synthesis (e.g., hypothyroidism)</p>
          </list-item>
          <list-item>
            <p>Certain drugs (e.g., valproic acid, ciprofloxacin, griseofulvin, hydroxyethyl starch)</p>
          </list-item>
        </list>
      </sec>
      <sec id="von-willebrand.Management">
        <title>Management</title>
        <sec id="von-willebrand.Evaluations_Following_Ini">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with von Willebrand disease (VWD), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>A personal and family history of bleeding to help predict severity and tailor treatment. Use of a bleeding assessment tool can facilitate standardized assessment [<xref ref-type="bibr" rid="von-willebrand.REF48">International Society on Thrombosis and Haemostasis 2011</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.tosetto.2011.1143">Tosetto et al 2011</xref>].</p>
            </list-item>
            <list-item>
              <p>A joint and muscle evaluation for those with type 3 VWD (musculoskeletal bleeding is rare in types 1 and 2 VWD).</p>
            </list-item>
            <list-item>
              <p>Screening for hepatitis B and C as well as HIV if the diagnosis is type 3 VWD or if the individual received blood products or plasma-derived clotting factor concentrates before 1985.</p>
            </list-item>
            <list-item>
              <p>Baseline serum concentration of iron and ferritin to assess iron stores, as many individuals with VWD (particularly women with menorrhagia) are iron deficient</p>
            </list-item>
            <list-item>
              <p>Gynecologic evaluation for women with menorrhagia [<xref ref-type="bibr" rid="von-willebrand.REF.demers.2005.707">Demers et al 2005</xref>]</p>
            </list-item>
            <list-item>
              <p>Medical genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="von-willebrand.Treatment_of_Manifestatio">
          <title>Treatment of Manifestations</title>
          <p>See <xref ref-type="bibr" rid="von-willebrand.REF.nichols.2008">Nichols et al [2008]</xref> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2516.2007.01643.x/full">full text</ext-link>) and <xref ref-type="bibr" rid="von-willebrand.REF.castaman.2013">Castaman et al [2013]</xref> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.haematologica.org/content/98/5/667.long">full text</ext-link>) for treatment guidelines.</p>
          <p>Individuals with VWD benefit from referral to a comprehensive bleeding disorders program for education, treatment, and genetic counseling.</p>
          <p>The two main treatments are desmopressin (1-deamino-8-D-arginine vasopressin [DDAVP]) and clotting factor concentrates containing both VWF and FVIII (VWF/FVIII concentrate). Individuals with VWD should receive prompt treatment for severe bleeding episodes.</p>
          <sec id="von-willebrand.Desmopressin">
            <title>Desmopressin</title>
            <p>Most individuals with type 1 VWD and some with type 2 VWD respond to intravenous or subcutaneous treatment with desmopressin [<xref ref-type="bibr" rid="von-willebrand.REF.castaman.2008.3531">Castaman et al 2008</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.federici.2008.5">Federici 2008</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.leissinger.2014.158">Leissinger et al 2014</xref>], which promotes release of stored VWF and raises levels three- to fourfold. Intranasal preparations are also available.</p>
            <p>Following VWD diagnosis, a desmopressin challenge is advisable to assess VWF response.</p>
            <p>Desmopressin is the treatment of choice for acute bleeding episodes or to cover surgery.</p>
            <p>Desmopressin has been used successfully to cover delivery in women with type 1 VWD and also for a proportion of pregnant women with type 2 VWD [<xref ref-type="bibr" rid="von-willebrand.REF.castaman.2010b.963">Castaman et al 2010b</xref>] (see <xref ref-type="sec" rid="von-willebrand.Pregnancy_Management">Pregnancy Management</xref>).</p>
            <p>In persons who do not tolerate desmopressin or who have a poor VWF response, clotting factor concentrate is required.</p>
            <p>Desmopressin is contraindicated in individuals with arteriovascular disease and in those older than age 70 years for whom VWF/FVIII concentrate is required.</p>
            <p>Note: Because desmopressin can cause hyponatremia (which can lead to seizures and coma), fluid intake should be restricted for 24 hours following its administration to minimize this risk.</p>
          </sec>
          <sec id="von-willebrand.Intravenous_Infusion_of_V">
            <title>Intravenous Infusion of VWF/FVIII Clotting Factor Concentrates</title>
            <p>In those who are non-responsive to desmopressin (i.e., VWF deficiency is not sufficiently corrected) and for those in whom desmopressin is contraindicated (see <xref ref-type="sec" rid="von-willebrand.Treatment_by_VWD_Type">Treatment by VWD Type</xref>), bleeding episodes can be prevented or controlled with intravenous infusion of virally inactivated plasma-derived clotting factor concentrates containing both VWF and FVIII [<xref ref-type="bibr" rid="von-willebrand.REF.federici.2007.15">Federici 2007</xref>]. Such concentrates are prepared from pooled blood donations from many donors. Virus inactivation procedures eliminate potential pathogens.</p>
          </sec>
          <sec id="von-willebrand.Indirect_Treatments">
            <title>Indirect Treatments</title>
            <p>In addition to treatments that directly increase VWF levels, individuals with VWD often benefit from indirect hemostatic treatments, including:</p>
            <list list-type="bullet">
              <list-item>
                <p>Fibrinolytic inhibitors (i.e., tranexamic acid for treatment or prevention of bleeding episodes);</p>
              </list-item>
              <list-item>
                <p>Hormonal treatments (i.e., the combined oral contraceptive pill for the treatment of menorrhagia).</p>
              </list-item>
            </list>
          </sec>
          <sec id="von-willebrand.Treatment_by_VWD_Type">
            <title>Treatment by VWD Type</title>
            <p><bold>Type 1 VWD.</bold> Treatments that directly increase VWF levels (e.g., desmopressin or VWF/FVIII clotting factor concentrates) are usually only needed for the treatment or prevention of severe bleeding, as with major trauma or surgery.</p>
            <p><xref ref-type="sec" rid="von-willebrand.Indirect_Treatments">Indirect treatment</xref> with fibrinolytic inhibitors or hormones is often effective.</p>
            <p><bold>Type 2A VWD.</bold> Treatment with clotting factor concentrates is usually only required for the treatment or prevention of severe bleeding episodes such as during surgery.</p>
            <p>Responsiveness to desmopressin is variable and should be confirmed prior to therapeutic use.</p>
            <p>Indirect treatments can be beneficial.</p>
            <p><bold>Type 2B VWD.</bold> Clotting factor concentrates are usually required to treat severe bleeding or at the time of surgery.</p>
            <p>Treatment with desmopressin should be undertaken cautiously as it can precipitate a worsening of any thrombocytopenia. People with certain pathogenic variants associated with mild or atypical 2B VWD, however, do not appear to develop thrombocytopenia when exposed to desmopressin. [<xref ref-type="bibr" rid="von-willebrand.REF.federici.2009.526">Federici et al 2009</xref>]</p>
            <p>Indirect treatments (i.e., fibrinolytic inhibitors) can be useful.</p>
            <p><bold>Type 2M VWD.</bold> Because desmopressin response is generally poor, VWF/FVIII concentrate is the treatment of choice.</p>
            <p><bold>Type 2N VWD.</bold> Desmopressin can be used for minor bleeding, but because the FVIII level will drop rapidly (as FVIII is not protected by VWF), concentrate containing VWF <bold>as well as</bold> FVIII is required to cover surgical procedures.</p>
            <p><bold>Type 3 VWD.</bold> Treatment often requires the repeated infusion of VWF/FVIII clotting factor concentrates [<xref ref-type="bibr" rid="von-willebrand.REF.franchini.2007.699">Franchini et al 2007</xref>].</p>
            <p>Desmopressin is not effective in type 3 VWD.</p>
            <p><xref ref-type="sec" rid="von-willebrand.Indirect_Treatments">Indirect treatments</xref> may also be beneficial.</p>
          </sec>
          <sec id="von-willebrand.Pediatric_Issues">
            <title>Pediatric Issues</title>
            <p>Special considerations for the care of infants and children with VWD include the following:</p>
            <list list-type="bullet">
              <list-item>
                <p>Infant males should be circumcised only after consultation with a pediatric hemostasis specialist.</p>
              </list-item>
              <list-item>
                <p>Desmopressin should be used with caution, particularly in those under age two years, because of the potential difficulty in restricting fluids in this age group.</p>
              </list-item>
              <list-item>
                <p>VWF levels are higher in the neonatal period; thus, phenotypic testing for milder forms of VWD should be delayed until later in childhood.</p>
              </list-item>
            </list>
          </sec>
        </sec>
        <sec id="von-willebrand.Prevention_of_Primary_Man">
          <title>Prevention of Primary Manifestations</title>
          <p>Individuals with type 3 VWD are often given prophylactic infusions of VWF/FVIII concentrates to prevent musculoskeletal bleeding and subsequent joint damage.</p>
        </sec>
        <sec id="von-willebrand.Prevention_of_Secondary_C">
          <title>Prevention of Secondary Complications</title>
          <p>Desmopressin should be used with caution, particularly in those under age two years, because of the potential difficulty in restricting fluids in this age group.</p>
          <p>Individuals with VWD should be vaccinated for hepatitis A and B [<xref ref-type="bibr" rid="von-willebrand.REF.nichols.2008">Nichols et al 2008</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.castaman.2013">Castaman et al 2013</xref>].</p>
          <p>Prevention of chronic joint disease is a concern for individuals with type 3 VWD; however, controversy exists regarding the specific schedule and dosing of prophylactic regimens. An international trial that investigated prophylactic treatment for symptoms including joint bleeding, nosebleeds, and menorrhagia concluded that rates of bleeding within individuals during prophylaxis were significantly lower than levels prior to prophylaxis [<xref ref-type="bibr" rid="von-willebrand.REF.berntorp.2010.189">Berntorp et al 2010</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.abshire.2013.76">Abshire et al 2013</xref>].</p>
        </sec>
        <sec id="von-willebrand.Surveillance">
          <title>Surveillance</title>
          <p>Individuals with milder forms of VWD can benefit from being followed by treatment centers with experience in the management of bleeding disorders.</p>
          <p>Individuals with type 3 VWD should be followed in experienced centers and should have periodic evaluations by a physiotherapist to monitor joint mobility.</p>
        </sec>
        <sec id="von-willebrand.AgentsCircumstances_to_Av">
          <title>Agents/Circumstances to Avoid</title>
          <p>Activities with a high risk of trauma, particularly head injury, should be avoided.</p>
          <p>Medications with effects on platelet function (ASA, clopidogrel, or NSAIDs) should be avoided as they can worsen bleeding symptoms.</p>
          <p>Infant males should be circumcised only after consultation with a pediatric hemostasis specialist.</p>
        </sec>
        <sec id="von-willebrand.Evaluation_of_Relatives_a">
          <title>Evaluation of Relatives at Risk</title>
          <p>Once the familial pathogenic variant(s) have been identified, at-risk relatives can be readily analyzed for the pathogenic variant(s) to allow early diagnosis and treatment as needed [<xref ref-type="bibr" rid="von-willebrand.REF.keeney.2008">Keeney et al 2008</xref>].</p>
          <p>See <xref ref-type="sec" rid="von-willebrand.Related_Genetic_Counselin">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="von-willebrand.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>VWF levels increase throughout pregnancy with the peak occurring in the third trimester. Nonetheless, pregnant women with VWD are at increased risk for bleeding complications and care should be provided in centers with experience in perinatal management of bleeding disorders [<xref ref-type="bibr" rid="von-willebrand.REF.james.2007.1165">James &#x00026; Jamison 2007</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.varughese.2007.730">Varughese &#x00026; Cohen 2007</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.james.2009">James et al 2009</xref>].</p>
          <p>Women with baseline VWF and FVIII levels of &#x0003e;30 IU/dL are likely to achieve normal levels by the time of delivery, whereas those with a basal level &#x0003c;20 IU/dL and those with baseline VWF:RCo/VWF:Ag ratio &#x0003c;0.6 are likely to require replacement therapy [<xref ref-type="bibr" rid="von-willebrand.REF.castaman.2013">Castaman et al 2013</xref>].</p>
          <p>Although deliveries should occur based on obstetric indications, instrumentation should be minimized [<xref ref-type="bibr" rid="von-willebrand.REF.demers.2005.707">Demers et al 2005</xref>].</p>
          <p>Delayed, secondary postpartum bleeding may be a problem. VWF level rapidly returns to pre-pregnancy level following delivery [<xref ref-type="bibr" rid="von-willebrand.REF.castaman.2013">Castaman et al 2013</xref>].</p>
        </sec>
        <sec id="von-willebrand.Therapies_Under_Investiga">
          <title>Therapies Under Investigation</title>
          <p>Recombinant VWF is in clinical trials and is expected to be available for patient use in the near future. It may largely replace use of plasma-derived VWF, as has happened for FVIII and FIX recombinant products [<xref ref-type="bibr" rid="von-willebrand.REF.turacek.2010.510">Turacek et al 2010</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.mannucci.2013.648">Mannucci et al 2013</xref>].</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="von-willebrand.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="von-willebrand.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Most von Willebrand disease (VWD) type 1, most type 2A, type 2B, and type 2M are inherited in an autosomal dominant manner.</p>
          <p>VWD type 2N, type 3, and some type 1 and type 2A are inherited in an autosomal recessive manner.</p>
          <p>A single case of uniparental disomy has been reported in type 3 VWD. The two copies of the pathogenic variant resulted from maternal uniparental isodisomy [<xref ref-type="bibr" rid="von-willebrand.REF.boisseau.2011.1567">Boisseau et al 2011</xref>].</p>
        </sec>
        <sec id="von-willebrand.Risk_to_Family_Members__A">
          <title>Risk to Family Members &#x02013; Autosomal Dominant Inheritance</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Most individuals diagnosed with one of the AD types of VWD have an affected parent.</p>
            </list-item>
            <list-item>
              <p>A proband with AD VWD may have the disorder as the result of a new gene pathogenic variant. The proportion of cases caused by a <italic toggle="yes">de novo</italic> variant is unknown.</p>
            </list-item>
            <list-item>
              <p>If the <italic toggle="yes">VWF</italic> pathogenic variant causing AD VWD found in the proband cannot be detected in the DNA of either parent, two possible explanations are germline mosaicism in a parent or <italic toggle="yes">de novo</italic> mutation in the proband. Neither possibility has been sufficiently investigated to comment on relative likelihood of occurrence.</p>
            </list-item>
            <list-item>
              <p>The family history of some individuals diagnosed with AD VWD may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the recognition of symptoms, or late significant hemostatic challenges in the affected parent. Therefore, an apparently negative family history cannot be confirmed unless appropriate evaluations (e.g., VWD hemostasis factor assays and/or molecular genetic testing if the proband&#x02019;s pathogenic variant is known) have been performed on the parents of the proband.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of the proband depends on the genetic status of the proband&#x02019;s parents.</p>
            </list-item>
            <list-item>
              <p>If a parent of the proband is affected, the risk to the sibs is 50%.</p>
            </list-item>
            <list-item>
              <p>The sibs of a proband with clinically unaffected parents are still at increased risk for the disorder because of the possibility of reduced penetrance in a parent.</p>
            </list-item>
            <list-item>
              <p>If the <italic toggle="yes">VWF</italic> variant found in the proband cannot be detected in the leukocyte DNA of either parent, the risk to sibs is low, but greater than that of the general population because of the possibility of germline mosaicism.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Each child of an individual with AD VWD has a 50% chance of inheriting the <italic toggle="yes">VWF</italic> pathogenic variant.</p>
          <p><bold>Other family members of a proband.</bold> The risk to other family members depends on the status of the proband's parents. If a parent is affected, his or her family members may be at risk.</p>
        </sec>
        <sec id="von-willebrand.Risk_to_Family_Members__A_1">
          <title>Risk to Family Members &#x02013; Autosomal Recessive Inheritance</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an individual with AR VWD are usually obligate heterozygotes (i.e., carriers of one <italic toggle="yes">VWF</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) of type 3 VWD are often asymptomatic. However, between 15% and 50% may show some mild bleeding symptoms and may be diagnosed with type 1 VWD [<xref ref-type="bibr" rid="von-willebrand.REF.nichols.2008">Nichols et al 2008</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.bowman.2013.512">Bowman et al 2013</xref>].</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) of type 2N VWD are often asymptomatic. However, a small proportion may show some mild bleeding symptoms and may be diagnosed with type 1 VWD.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>When both parents are carriers of a <italic toggle="yes">VWF</italic> pathogenic variant, each sib of an individual with AR VWD has at conception a 25% chance of being affected, a 50% chance of being a carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.</p>
            </list-item>
            <list-item>
              <p>When only one parent is a carrier (in the case of uniparental isodisomy [<xref ref-type="bibr" rid="von-willebrand.REF.boisseau.2011.1567">Boisseau et al 2011</xref>]), the risk to sibs of a proband to be affected is unknown, but likely very low (&#x0003c;1%). However, each sib has a 50% chance of being a carrier and a 50% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) of type 3 VWD are often asymptomatic. However, between 15% and 50% may show some mild bleeding symptoms and may be diagnosed with type 1 VWD [<xref ref-type="bibr" rid="von-willebrand.REF.nichols.2008">Nichols et al 2008</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.bowman.2013.512">Bowman et al 2013</xref>].</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with AR VWD are obligate heterozygotes (carriers) for a pathogenic variant in <italic toggle="yes">VWF</italic>.</p>
          <p><bold>Other family members of a proband.</bold> Each sib of the proband&#x02019;s parents is at 50% risk of being a carrier of a <italic toggle="yes">VWF</italic> pathogenic variant.</p>
        </sec>
        <sec id="von-willebrand.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing for at-risk family members is possible once the pathogenic variant(s) have been identified in the family.</p>
        </sec>
        <sec id="von-willebrand.Related_Genetic_Counselin">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="von-willebrand.Evaluation_of_Relatives_a">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> pathogenic variant</bold>. When neither parent of a proband with an autosomal dominant condition has the pathogenic variant or clinical evidence of the disorder, it is likely that the proband has a <italic toggle="yes">de novo</italic> pathogenic variant. However, possible non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="von-willebrand.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>Once the <italic toggle="yes">VWF</italic> pathogenic variant(s) have been identified in an affected family member, prenatal testing or preimplantation genetic diagnosis for a pregnancy at increased risk (generally for type 3 VWD) may be an option that a couple may wish to consider.</p>
          <p>Prenatal diagnosis of a treatable condition may be controversial if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider this to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="von-willebrand.Resources">
        <title>Resources</title>
      </sec>
      <sec id="von-willebrand.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure</bold>. <italic toggle="yes">VWF</italic> spans 178 kb of genomic DNA in 52 exons that encode an 8.8-kb mRNA and a 2813-amino acid protein [<xref ref-type="bibr" rid="von-willebrand.REF.sadler.1998.395">Sadler 1998</xref>]. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="von-willebrand" object-id="von-willebrand.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Benign allelic variants.</bold> Benign variants are extremely common. Currently, more than 500 variants are documented in the exons and closely flanking <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?chooseRs=all&#x00026;go=Go&#x00026;locusId=7450">intronic sequences</ext-link>; benign amino acid substitutions are predicted at 80 residues (<xref ref-type="table" rid="von-willebrand.T.selected_vwf_benign_all">Table 4</xref>). As ethnic groups that are not of northern European origin are being examined, many additional benign variants are being identified [<xref ref-type="bibr" rid="von-willebrand.REF.bellissimo.2012.2135">Bellissimo et al 2012</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.johnsen.2013.590">Johnsen et al 2013</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.zhou.2014.e84810">Zhou et al 2014</xref>]. In one study, an average of 17 heterozygous benign sequence variants were identified in each individual screened for <italic toggle="yes">VWF</italic> pathogenic variants [<xref ref-type="bibr" rid="von-willebrand.REF.hashemi_soteh.2007.550">Hashemi Soteh et al 2007</xref>]. This large number of benign variants in <italic toggle="yes">VWF</italic>, along with the large size of the gene and the presence of a partial pseudogene, <italic toggle="yes">VWFP</italic> (exons 23-34), can make full gene sequencing and data interpretation difficult.</p>
        <p>For type 1 von Willebrand disease (VWD), approximately 10% of affected individuals had more than one sequence variant identified; some variants were in <italic toggle="yes">cis</italic> (on the same allele), whereas others were in <italic toggle="yes">trans</italic> [<xref ref-type="bibr" rid="von-willebrand.REF.cumming.2006.630">Cumming et al 2006</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.goodeve.2007.112">Goodeve et al 2007</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.james.2007a.145">James et al 2007a</xref>]. Such observations underscore the difficulty of identifying pathogenic versus benign allelic variants. Similarly, sequence variants in the promoter region have been identified, and the pathogenicity of a 13-base pair deletion in a type 1 VWD family has been confirmed [<xref ref-type="bibr" rid="von-willebrand.REF.othman.2010.3645">Othman et al 2010</xref>].</p>
        <p>Benign allelic variants useful for linkage analysis are summarized in <xref ref-type="table" rid="von-willebrand.T.selected_vwf_benign_all">Table 4</xref> and include: short tandem repeats in the promoter and intron 40 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=41402545">rs41402545</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=36115023">rs36115023</ext-link>) [<xref ref-type="bibr" rid="von-willebrand.REF.vidal.2005.976">Vidal et al 2005</xref>] and a large number of common single nucleotide variants.</p>
        <table-wrap id="von-willebrand.T.selected_vwf_benign_all" position="anchor" orientation="portrait">
          <label>Table 4. </label>
          <caption>
            <p>Selected <italic toggle="yes">VWF</italic> Benign Allelic Variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change</th>
                <th id="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">VWF Exon/ Intron</th>
                <th id="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference SNP Number</th>
                <th id="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_5" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Restriction Site/ Type of Polymorphism</th>
                <th id="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_6" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1451A&#x0003e;G&#x000a0;<sup>1</sup><hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.His484Arg<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Exon 13<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1800378">rs1800378</ext-link>
                  <hr/>
                </td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Rsa I<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_6" rowspan="11" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_000552.3">NM_000552.3</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NP_000543.2">NP_000543.2</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1946-19_1946-17dupCTT&#x000a0;<sup>1</sup><hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">None<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Intron 15<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=10622288">rs10622288</ext-link>
                  <hr/>
                </td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">3-bp insertion/deletion<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.2365A&#x0003e;G&#x000a0;<sup>1</sup><hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Thr789Ala<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Exon 18<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1063856">rs1063856</ext-link>
                  <hr/>
                </td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Rsa I<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.2555A&#x0003e;G<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gln852Arg<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Exon 20<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=216321">rs216321</ext-link>
                  <hr/>
                </td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Nla IV<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.4141A&#x0003e;G&#x000a0;<sup>1</sup><hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Thr1381Ala<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Exon 28<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=216311">rs216311</ext-link>
                  <hr/>
                </td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Hph I<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.4414G&#x0003e;C<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Asp1472His<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Exon 28<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1800383">rs1800383</ext-link>
                  <hr/>
                </td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">RleA I<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.4641C&#x0003e;T&#x000a0;<sup>1</sup><hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Thr1547Thr<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Exon 28<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=216310">rs216310</ext-link>
                  <hr/>
                </td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">BstE II<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.6187C&#x0003e;T<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Pro2063Ser<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Exon 36<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">NA<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.6977-542_6977-541ins24<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">None<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Intron 40<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=36115023">rs36115023</ext-link>
                  <hr/>
                </td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Deletion/ insertion polymorphism<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.6977-715_6977-714ins16<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">None<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Intron 40<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=41402545">rs41402545 </ext-link>
                  <hr/>
                </td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Deletion/ insertion polymorphism<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.8113G&#x0003e;A</td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly2705Arg</td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Exon 49</td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7962217">rs7962217</ext-link>
                </td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_benign_all_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1"/>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Only a small proportion of common non-synonymous variants are listed.</p>
            </fn>
            <fn id="von-willebrand.TF.4.1">
              <label>1. </label>
              <p>Benign variants that may be useful for linkage analysis because they are common in several ethnic groups and/or affect the cleavage site of a well-behaved restriction enzyme</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Pathogenic allelic variants.</bold> Most cases of VWD result from single nucleotide substitutions (<xref ref-type="table" rid="von-willebrand.T.selected_vwf_pathogenic">Table 5</xref>, <xref ref-type="fig" rid="von-willebrand.F1">Figure 1</xref>) [<xref ref-type="bibr" rid="von-willebrand.REF.james.2006.546">James &#x00026; Lillicrap 2006</xref>]. Qualitative deficiency (type 2 VWD) results from pathogenic missense variants in functionally important areas of VWF. Partial quantitative deficiency in type 1 VWD is mostly associated with missense variants. Severe quantitative deficiency in type 3 VWD mostly results from homozygosity or compound heterozygosity for that result in null alleles, but includes a small proportion of missense variants. Pathogenic variants are cataloged (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.vwf.group.shef.ac.uk/index.html">ISTH-SSC VWF Database</ext-link>).</p>
        <table-wrap id="von-willebrand.T.selected_vwf_pathogenic" position="anchor" orientation="portrait">
          <label>Table 5. </label>
          <caption>
            <p>Selected <italic toggle="yes">VWF</italic> Pathogenic Variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">VWD Type&#x000a0;<sup>1</sup></th>
                <th id="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change</th>
                <th id="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">VWF Exon</th>
                <th id="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_5" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">1<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.3614G&#x0003e;A<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg1205His<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">27<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_5" rowspan="16" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_000552.3">NM_000552.3</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NP_000543.2">NP_000543.2</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">1<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.4751A&#x0003e;G<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Tyr1584Cys<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">28<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">2A<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.4517C&#x0003e;T<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ser1506Leu<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">28<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">2A<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.4789C&#x0003e;T<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg1597Trp<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">28<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">2B<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.3797C&#x0003e;T<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Pro1266Leu<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">28<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">2B<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.3916C&#x0003e;T<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg1306Trp<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">28<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">2B<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.3946G&#x0003e;A<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Val1316Met<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">28<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">2B<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.4022G&#x0003e;A<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg1341Gln<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">28<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">2M<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.3835G&#x0003e;A<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Val1279Ile<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">28<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">2M<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.4273A&#x0003e;T<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ile1425Phe<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">28<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">2N<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.2372C&#x0003e;T<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Thr791Met<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">18<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">2N<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.2446C&#x0003e;T<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg816Trp<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">19<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">2N<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.2561G&#x0003e;A<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg854Gln<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">20<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">3<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.2435delC<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Pro812ArgfsTer31<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">18<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">3<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.4975C&#x0003e;T<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg1659Ter<hr/></td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">28<hr/></td>
              </tr>
              <tr>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">3</td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.7603C&#x0003e;T</td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg2535Ter</td>
                <td headers="hd_h_von-willebrand.T.selected_vwf_pathogenic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">45</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="von-willebrand.TF.5.1">
              <label>1. </label>
              <p>Examples of the most frequent variants identified in each VWD type are shown. See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.vwf.group.shef.ac.uk/index.html">ISTH-SSC VWF Database</ext-link> for further information on allele variants and frequencies.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold> The 2813-amino acid VWF protein comprises a 22-amino acid signal peptide, a 741-amino acid propeptide, and a 2050-amino acid mature protein [<xref ref-type="bibr" rid="von-willebrand.REF.sadler.1998.395">Sadler 1998</xref>]. The recently revised domain structure of VWF protein [<xref ref-type="bibr" rid="von-willebrand.REF.zhou.2012.449">Zhou et al 2012</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.valentijn.2013.581">Valentijn &#x00026; Eikenboom 2013</xref>] is shown in <xref ref-type="fig" rid="von-willebrand.F1">Figure 1</xref>. During synthesis, tail-to-tail disulfide-linked dimers are formed through the CK domains, followed by head-to-head VWF oligomers. Disulfide isomerase sites in the propeptide catalyze this process. VWF has two sites of synthesis: endothelial cells and megakaryocytes, the precursors of platelets. VWF secreted from endothelial cells and platelets consists of multimers up to 40 subunits (dimers) in length. The propeptide is cleaved by furin between amino acids 763 and 764 during multimer production and the propeptide (VWFpp) is secreted into the plasma along with VWF. The ratio between VWFpp and mature VWF (VWF:Ag) can be used to estimate relative half-life of mature VWF [<xref ref-type="bibr" rid="von-willebrand.REF.haberichter.2008.4979">Haberichter et al 2008</xref>]; the ratio also provides information about pathogenic mechanism [<xref ref-type="bibr" rid="von-willebrand.REF.eikenboom.2013.2336">Eikenboom et al 2013</xref>].</p>
        <p>To render HMW VWF less thrombogenic, it is cleaved by ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 motif) between amino acids 1605 and 1606 following secretion. This multimer proteolysis produces the characteristic &#x0201c;triplet&#x0201d; pattern of satellite bands flanking each main multimer band observed on multimer analysis gels, abnormalities in which can give clues as to VWD subtype [<xref ref-type="bibr" rid="von-willebrand.REF.schneppenheim.2011.209">Schneppenheim &#x00026; Budde 2011</xref>].</p>
        <p>VWF has two key functions: (1) binding collagen in the sub-endothelium at sites of vascular damage, which initiates repair through platelet recruitment and clot formation plus binding; and (2) protecting FVIII from premature proteolytic degradation and transporting it to sites where fibrin generation is required.</p>
        <p><bold>Abnormal gene product.</bold> Abnormalities in VWF depend on the type of pathogenic variant. The molecular consequences of both the protein and nucleotide abnormality result in different VWD types:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Type 1.</bold> Missense variants predominate but may affect VWF through different mechanisms. As molecular genetic testing has been undertaken in type 1 VWD only recently, in many cases pathogenic mechanisms have not yet been ascertained.</p>
            <list list-type="bullet">
              <list-item>
                <p>Missense variants predominantly in the D3 and A1 domains [<xref ref-type="bibr" rid="von-willebrand.REF.haberichter.2008.4979">Haberichter et al 2008</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.millar.2008.916">Millar et al 2008</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.eikenboom.2013.2336">Eikenboom et al 2013</xref>] reduce the residence time of VWF in plasma by many fold. <xref ref-type="table" rid="von-willebrand.T.selected_vwf_benign_all">p.Arg1205His</xref>, the so-called &#x0201c;Vicenza&#x0201d; variant, is the best characterized and most common of these pathogenic variants. Such pathogenic variants have been referred to as type 1 clearance (1C) [<xref ref-type="bibr" rid="von-willebrand.REF.haberichter.2006.3344">Haberichter et al 2006</xref>], although this is not a VWD category that has been recognized by the International Society on Thrombosis and Haemostasis Scientific and Standardisation Committee on VWF (ISTH SSC on VWF) [<xref ref-type="bibr" rid="von-willebrand.REF.sadler.2006.2103">Sadler et al 2006</xref>].</p>
              </list-item>
              <list-item>
                <p>Intracellular retention is a common mechanism for type 1 VWD pathogenicity [<xref ref-type="bibr" rid="von-willebrand.REF.eikenboom.2009.1304">Eikenboom et al 2009</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.eikenboom.2013.2336">Eikenboom et al 2013</xref>].</p>
              </list-item>
              <list-item>
                <p>Haploinsufficiency resulting from a heterozygous null allele results in reduced VWF expression in a small proportion of cases.</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p><bold>Type 2A.</bold> Missense variants result in a loss of high and sometimes intermediate molecular-weight multimers through a number of mechanisms which may act together: (1) impaired dimer assembly, (2) impaired multimer assembly, (3) enhanced susceptibility to VWF cleaving protease encoded by <italic toggle="yes">ADAMTS13</italic> [<xref ref-type="bibr" rid="von-willebrand.REF.hassenpflug.2006.2339">Hassenpflug et al 2006</xref>], and (4) intracellular retention [<xref ref-type="bibr" rid="von-willebrand.REF.schneppenheim.2010.4894">Schneppenheim et al 2010</xref>]. All result in the loss of HMW forms of VWF with fewer GpIb&#x003b1; binding sites and less effective platelet clot formation.</p>
          </list-item>
          <list-item>
            <p><bold>Type 2B.</bold> Missense variants enhance the ability of VWF to bind platelet glycoprotein GpIb&#x003b1; such that binding occurs spontaneously without requiring the normal conformational change in VWF that results from its binding to collagen following subendothelial damage. The platelet-VWF complex is removed from circulation and can result in thrombocytopenia. Higher molecular-weight multimers bind platelets preferentially,and so are lost to a greater extent. VWF binding to platelets can also enhance susceptibility to the VWF cleaving protease (encoded by <italic toggle="yes">ADAMTS13</italic>), which also contributes to the loss of HMW multimers. Enhanced clearance of VWF from circulation also appears to be a significant contributor to the phenotype [<xref ref-type="bibr" rid="von-willebrand.REF.casonato.2010.1366">Casonato et al 2010</xref>]. Pathogenic variants affecting p.Pro1266Leu and p.Arg1379Cys may only demonstrate enhanced GpIb&#x003b1; binding but no thrombocytopenia or HMW multimer loss [<xref ref-type="bibr" rid="von-willebrand.REF.federici.2009.526">Federici et al 2009</xref>, <xref ref-type="bibr" rid="von-willebrand.REF.casonato.2010.1366">Casonato et al 2010</xref>].</p>
          </list-item>
          <list-item>
            <p><bold>Type 2M.</bold> VWF is poor at binding GpIb&#x003b1;, often as a result of a missense variant in the A1 domain (see <xref ref-type="fig" rid="von-willebrand.F1">Figure 1</xref>) altering protein confirmation and rendering the domain incapable of binding GpIb&#x003b1;, but without the loss of HMW multimers seen in type 2A [<xref ref-type="bibr" rid="von-willebrand.REF.james.2007b.1914">James et al 2007b</xref>]. Alternatively, missense variants in the A3 domain reduce affinity for subendothelial collagen, with the result that VWF lacks affinity for GpIb&#x003b1;.</p>
          </list-item>
          <list-item>
            <p><bold>Type 2N.</bold> Affinity of VWF for FVIII is reduced as a result of alteration of key amino acids in the FVIII binding site or of conformational change having an indirect effect on VWF-FVIII binding.</p>
          </list-item>
          <list-item>
            <p><bold>Type 3.</bold> Both alleles are affected by pathogenic variants (null or missense) that result in lack of VWF secretion from the cell. Most individuals with type 3 VWD have two null alleles and therefore produce no significant quantity of VWF. Approximately 20% of alleles have missense variants often affecting the D1 or A1-A2 domains (see <xref ref-type="fig" rid="von-willebrand.F1">Figure 1</xref>). Some may impair VWF multimerization, resulting in intracellular retention and lack of secretion into plasma.</p>
          </list-item>
        </list>
      </sec>
      <sec id="von-willebrand.References">
        <title>References</title>
        <sec id="von-willebrand.Published_GuidelinesConse">
          <title>Published Guidelines/Consensus Statements</title>
          <ref-list id="von-willebrand.Published_GuidelinesConse.reflist0">
            <ref id="von-willebrand.REF.castaman.2013">
              <mixed-citation publication-type="webpage">Castaman G, Goodeve A, Eikenboom J; European Group on von Willebrand Disease. Principles of care for the diagnosis and treatment of von Willebrand disease. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.haematologica.org/content/98/5/667.long">online</ext-link>. 2013. Accessed 1-19-2016.</mixed-citation>
            </ref>
            <ref id="von-willebrand.REF.james.2009">
              <mixed-citation publication-type="webpage">James AH, Kouides PA, Abdul-Kadir R, Edlund M, Federici AB, Halimeh S, Kamphuisen PW, Konkle BA, Mart&#x000ed;nez-Perez O, McLintock C, Peyvandi F, Winikoff R. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ajog.org/article/S0002-9378%2809%2900410-4/fulltext">online</ext-link>. 2009. Accessed 1-19-2016.</mixed-citation>
            </ref>
            <ref id="von-willebrand.REF.keeney.2008">
              <mixed-citation publication-type="webpage">Keeney S, Bowen D, Cumming A, Enayat S, Goodeve A, Hill M. The molecular analysis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organisation Haemophilia Genetics Laboratory Network. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2516.2008.01813.x/abstract">online</ext-link>. 2008. Accessed 1-19-2016.</mixed-citation>
            </ref>
            <ref id="von-willebrand.REF.nichols.2008">
              <mixed-citation publication-type="webpage">Nichols WL, Hultin MB, James AH, Manco-Johnson MJ, Montgomery RR, Ortel TL, Rick ME, Sadler JE, Weinstein M, Yawn BP. Von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2516.2007.01643.x/full">online</ext-link>. 2008. Accessed 1-19-2016.</mixed-citation>
            </ref>
            <ref id="von-willebrand.REF5">
              <mixed-citation publication-type="webpage">NHLBI. The diagnosis, evaluation, and management of von Willebrand disease (includes a more detailed version and synopsis of the Nichols et al 2008 guidelines and patient education information). Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nhlbi.nih.gov/files/docs/guidelines/vwd.pdf">online</ext-link>. Accessed 1-19-2016.</mixed-citation>
            </ref>
            <ref id="von-willebrand.REF.sadler">
              <mixed-citation publication-type="webpage">Sadler JE. Von Willebrand disease. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <italic toggle="yes">The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID).</italic> New York, NY: McGraw-Hill. Chap 174. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ommbid.mhmedical.com/content.aspx?bookid=971&#x00026;sectionid=62650434">online</ext-link>. Accessed 1-19-2016.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="von-willebrand.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="von-willebrand.Literature_Cited.reflist0">
            <ref id="von-willebrand.REF.abshire.2013.76">
              <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Abshire</surname><given-names>TC</given-names></name><name name-style="western"><surname>Federici</surname><given-names>AB</given-names></name><name name-style="western"><surname>Alv&#x000e1;rez</surname><given-names>MT</given-names></name><name name-style="western"><surname>Bowen</surname><given-names>J</given-names></name><name name-style="western"><surname>Carcao</surname><given-names>MD</given-names></name><name name-style="western"><surname>Cox Gill</surname><given-names>J</given-names></name><name name-style="western"><surname>Key</surname><given-names>NS</given-names></name><name name-style="western"><surname>Kouides</surname><given-names>PA</given-names></name><name name-style="western"><surname>Kurnik</surname><given-names>K</given-names></name><name name-style="western"><surname>Lail</surname><given-names>AE</given-names></name><name name-style="western"><surname>Leebeek</surname><given-names>FW</given-names></name><name name-style="western"><surname>Makris</surname><given-names>M</given-names></name><name name-style="western"><surname>Mannucci</surname><given-names>PM</given-names></name><name name-style="western"><surname>Winikoff</surname><given-names>R</given-names></name><name name-style="western"><surname>Berntorp</surname><given-names>E</given-names></name></person-group>VWD PN<year>2013</year><article-title>Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN).</article-title><source>Haemophilia.</source><volume>19</volume><fpage>76</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">22823000</pub-id></mixed-citation>
            </ref>
            <ref id="von-willebrand.REF.bellissimo.2012.2135">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bellissimo</surname>
                    <given-names>DB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christopherson</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flood</surname>
                    <given-names>VH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gill</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedman</surname>
                    <given-names>KD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haberichter</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shapiro</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abshire</surname>
                    <given-names>TC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leissinger</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoots</surname>
                    <given-names>WK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lusher</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ragni</surname>
                    <given-names>MV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montgomery</surname>
                    <given-names>RR</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population.</article-title>
                <source>Blood.</source>
                <volume>119</volume>
                <fpage>2135</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">22197721</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.berntorp.2010.189">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Berntorp</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Moerloose</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ljung</surname>
                    <given-names>RC</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>The role of prophylaxis in bleeding disorders</article-title>
                <source>Haemophilia.</source>
                <volume>16</volume>
                <fpage>189</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">20590880</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.boisseau.2013">
              <mixed-citation publication-type="confproc">Boisseau P, Ternisien C, Caron C, Giraud M, Talarmain P, Zawadzki C, Beziau S, Fressinaud E, Goudemand J, Veyradier A. Incidence of large VWF gene deletions and duplications in the French cohort of 1182 patients with von Willebrand disease (VWD). Amsterdam, Netherlands: XXIV Congress of the International Society on Thrombosis and Haemostasis. 2013.</mixed-citation>
            </ref>
            <ref id="von-willebrand.REF.boisseau.2011.1567">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Boisseau</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giraud</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ternisien</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Veyradier</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fressinaud</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lefrancois</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bezieau</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fouassier</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>An unexpected transmission of von Willebrand disease type 3: the first case of maternal uniparental disomy 12.</article-title>
                <source>Haematologica.</source>
                <volume>96</volume>
                <fpage>1567</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">21750090</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.bowman.2013.512">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bowman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tuttle</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Notley</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tinlin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deforest</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leggo</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blanchette</surname>
                    <given-names>VS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lillicrap</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>James</surname>
                    <given-names>P</given-names>
                  </name>
                  <collab>Association of Hemophilia Clinic Directors of Canada</collab>
                </person-group>
                <year>2013</year>
                <article-title>The genetics of Canadian type 3 von Willebrand disease: further evidence for co-dominant inheritance of mutant alleles.</article-title>
                <source>J Thromb Haemost.</source>
                <volume>11</volume>
                <fpage>512</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">23311757</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.bowman.2008.2062">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bowman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mundell</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grabell</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hopman</surname>
                    <given-names>WM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rapson</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lillicrap</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>James</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease.</article-title>
                <source>J Thromb Haemost</source>
                <volume>6</volume>
                <fpage>2062</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">18983516</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.bowman.2009.1418">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bowman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riddel</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rand</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tosetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silva</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>James</surname>
                    <given-names>PD</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire.</article-title>
                <source>J Thromb Haemost</source>
                <volume>7</volume>
                <fpage>1418</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">19496919</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.budde.2006.514">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Budde</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pieconka</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Will</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneppenheim</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Laboratory testing for von Willebrand disease: contribution of multimer analysis to diagnosis and classification.</article-title>
                <source>Semin Thromb Hemost</source>
                <volume>32</volume>
                <fpage>514</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">16862525</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.budde.2008.762">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Budde</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneppenheim</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eikenboom</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goodeve</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Will</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drewke</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castaman</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodeghiero</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Federici</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Batlle</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perez</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazurier</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goudemand</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ingerslev</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Habart</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vorlova</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmberg</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lethagen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hill</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peake</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD).</article-title>
                <source>J Thromb Haemost</source>
                <volume>6</volume>
                <fpage>762</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">18315556</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.casari.2010.5371">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Casari</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pinotti</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lancellotti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adinolfi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casonato</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Cristofaro</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernardi</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>The dominant-negative von Willebrand factor gene deletion p.P1105_C1926delinsR: molecular mechanism and modulation.</article-title>
                <source>Blood.</source>
                <volume>116</volume>
                <fpage>5371</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">20570857</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.casonato.2010.1366">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Casonato</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallinaro</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cattini</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pontara</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Padrini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertomoro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daidone</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pagnan</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia.</article-title>
                <source>Haematologica.</source>
                <volume>95</volume>
                <fpage>1366</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">20305138</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.casonato.2007.194">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Casonato</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pontara</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sartorello</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cattini</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perutelli</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertomoro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallinaro</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pagnan</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Identifying carriers of type 2N von Willebrand disease: procedures and significance.</article-title>
                <source>Clin Appl Thromb Hemost</source>
                <volume>13</volume>
                <fpage>194</fpage>
                <lpage>200</lpage>
                <pub-id pub-id-type="pmid">17456630</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.castaman.2012.632">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Castaman</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Federici</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tosetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>La Marca</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stufano</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mannucci</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodeghiero</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients.</article-title>
                <source>J Thromb Haemost.</source>
                <volume>10</volume>
                <fpage>632</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">22329792</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.castaman.2013.667">
              <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Castaman</surname><given-names>G</given-names></name><name name-style="western"><surname>Goodeve</surname><given-names>A</given-names></name><name name-style="western"><surname>Eikenboom</surname><given-names>J</given-names></name></person-group>European Group on von Willebrand D<year>2013</year><article-title>Principles of care for the diagnosis and treatment of von Willebrand disease.</article-title><source>Haematologica.</source><volume>98</volume><fpage>667</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">23633542</pub-id></mixed-citation>
            </ref>
            <ref id="von-willebrand.REF.castaman.2008.3531">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Castaman</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lethagen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Federici</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tosetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goodeve</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Budde</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Batlle</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazurier</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fressinaud</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goudemand</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eikenboom</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneppenheim</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ingerslev</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vorlova</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Habart</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmberg</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hill</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peake</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodeghiero</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Response to desmopressin is influenced by the genotype and phenotype in type 1 Von Willebrand Disease (VWD): results from the European study MCMDM-1VWD.</article-title>
                <source>Blood.</source>
                <volume>111</volume>
                <fpage>3531</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">18230755</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.castaman.2010a.227">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Castaman</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tosetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cappelletti</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goodeve</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Federici</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Batlle</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goudemand</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eikenboom</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneppenheim</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Budde</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ingerslev</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lethagen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hill</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peake</surname>
                    <given-names>IR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodeghiero</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2010a</year>
                <article-title>Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD.</article-title>
                <source>Thromb Res.</source>
                <volume>126</volume>
                <fpage>227</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">20650506</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.castaman.2010b.963">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Castaman</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tosetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodeghiero</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2010b</year>
                <article-title>Pregnancy and delivery in women with von Willebrand's disease and different von Willebrand factor mutations.</article-title>
                <source>Haematologica.</source>
                <volume>95</volume>
                <fpage>963</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">19951969</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.cumming.2006.630">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cumming</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grundy</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keeney</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lester</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Enayat</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guilliatt</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowen</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keeling</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hill</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bolton-Maggs</surname>
                    <given-names>PH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hay</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease.</article-title>
                <source>Thromb Haemost</source>
                <volume>96</volume>
                <fpage>630</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">17080221</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.cumming.2011">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cumming</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keeney</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jenkins</surname>
                    <given-names>PV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nash</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Donnell</surname>
                    <given-names>JS</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Clinical utility gene card for: von Willebrand disease.</article-title>
                <source>Eur J Hum Genet</source>
                <volume>19</volume>
                <issue>5</issue>
                <pub-id pub-id-type="pmid">21206511</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.davies.2007.2840">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Davies</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>PW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hathaway</surname>
                    <given-names>LS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowen</surname>
                    <given-names>DJ</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Effect of von Willebrand factor Y/C1584 on in vivo protein level and function and interaction with ABO blood group.</article-title>
                <source>Blood</source>
                <volume>109</volume>
                <fpage>2840</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">17119126</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.demers.2005.707">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Demers</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Derzko</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>David</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Douglas</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Gynaecological and obstetric management of women with inherited bleeding disorders.</article-title>
                <source>J Obstet Gynaecol Can.</source>
                <volume>27</volume>
                <fpage>707</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">16100628</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.eikenboom.2013.2336">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Eikenboom</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Federici</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dirven</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castaman</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodeghiero</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Budde</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneppenheim</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Batlle</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Canciani</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goudemand</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peake</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goodeve</surname>
                    <given-names>A</given-names>
                  </name>
                  <collab>MCMDM-1VWD Study Group</collab>
                </person-group>
                <year>2013</year>
                <article-title>VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease.</article-title>
                <source>Blood.</source>
                <volume>121</volume>
                <fpage>2336</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">23349392</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.eikenboom.2009.1304">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Eikenboom</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hilbert</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ribba</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hommais</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Habart</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Messenger</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Buhairan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guilliatt</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lester</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazurier</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fressinaud</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Budde</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Will</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneppenheim</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Obser</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marggraf</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eckert</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castaman</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodeghiero</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Federici</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Battle</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goudemand</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ingerslev</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lethagen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hill</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peake</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goodeve</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Expression of 14 von Willebrand factor mutations identifice in patients with type 1 von Willebrand disease from the MCMDM-1VWD study.</article-title>
                <source>J Thromb Haemost</source>
                <volume>7</volume>
                <fpage>1304</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">19566550</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.favaloro.2008.113">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Favaloro</surname>
                    <given-names>EJ</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin?</article-title>
                <source>Semin Thromb Hemost</source>
                <volume>34</volume>
                <fpage>113</fpage>
                <lpage>27</lpage>
                <pub-id pub-id-type="pmid">18393148</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.favaloro.2007.623">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Favaloro</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patterson</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Denholm</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mead</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gilbert</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Estell</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>George</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>MP</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Differential identification of a rare form of platelet-type (pseudo-) von Willebrand disease (VWD) from Type 2B VWD using a simplified ristocetin-induced-platelet-agglutination mixing assay and confirmed by genetic analysis.</article-title>
                <source>Br J Haematol</source>
                <volume>139</volume>
                <fpage>623</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">17916098</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.federici.2006.s48">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Federici</surname>
                    <given-names>AB</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders</article-title>
                <source>Semin Hematol</source>
                <volume>43</volume>
                <fpage>S48</fpage>
                <lpage>58</lpage>
                <pub-id pub-id-type="pmid">16427386</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.federici.2007.15">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Federici</surname>
                    <given-names>AB</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO.WILL Study.</article-title>
                <source>Haemophilia.</source>
                <volume>13</volume>
                <supplement>Suppl 5</supplement>
                <fpage>15</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">18078393</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.federici.2008.5">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Federici</surname>
                    <given-names>AB</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007).</article-title>
                <source>Haemophilia.</source>
                <volume>14</volume>
                <fpage>5</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">18173689</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.federici.2013.191">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Federici</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Budde</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castaman</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rand</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tiede</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update.</article-title>
                <source>Semin Thromb Hemost.</source>
                <volume>39</volume>
                <fpage>191</fpage>
                <lpage>201</lpage>
                <pub-id pub-id-type="pmid">23397553</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.federici.2009.526">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Federici</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mannucci</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castaman</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baronciani</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bucciarelli</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Canciani</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pecci</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lenting</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Groot</surname>
                    <given-names>PG</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients.</article-title>
                <source>Blood</source>
                <volume>113</volume>
                <fpage>526</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">18805962</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.flood.2012.1417">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Flood</surname>
                    <given-names>VH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gill</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christopherson</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bellissimo</surname>
                    <given-names>DB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedman</surname>
                    <given-names>KD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haberichter</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lentz</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montgomery</surname>
                    <given-names>RR</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Critical von Willebrand factor A1 domain residues influence type VI collagen binding.</article-title>
                <source>J Thromb Haemost.</source>
                <volume>10</volume>
                <fpage>1417</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">22507569</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.flood.2013.684">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Flood</surname>
                    <given-names>VH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gill</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedman</surname>
                    <given-names>KD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christopherson</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacobi</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffmann</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montgomery</surname>
                    <given-names>RR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haberichter</surname>
                    <given-names>SL</given-names>
                  </name>
                  <collab>Zimmerman Program Investigators</collab>
                </person-group>
                <year>2013</year>
                <article-title>Collagen binding provides a sensitive screen for variant von Willebrand disease.</article-title>
                <source>Clin Chem.</source>
                <volume>59</volume>
                <fpage>684</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">23340442</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.franchini.2008.91">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Franchini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montagnana</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lippi</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Clinical, laboratory and therapeutic aspects of platelet-type von Willebrand disease.</article-title>
                <source>Int J Lab Hematol</source>
                <volume>30</volume>
                <fpage>91</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">18333841</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.franchini.2007.699">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Franchini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Targher</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lippi</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Prophylaxis in von Willebrand disease.</article-title>
                <source>Ann Hematol</source>
                <volume>86</volume>
                <fpage>699</fpage>
                <lpage>704</lpage>
                <pub-id pub-id-type="pmid">17634944</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.goodeve.2007.112">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Goodeve</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eikenboom</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castaman</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodeghiero</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Federici</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Batlle</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazurier</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goudemand</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneppenheim</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Budde</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ingerslev</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Habart</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vorlova</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmberg</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lethagen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hill</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hashemi Soteh</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baronciani</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hallden</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guilliatt</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lester</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peake</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD).</article-title>
                <source>Blood</source>
                <volume>109</volume>
                <fpage>112</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">16985174</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.haberichter.2006.3344">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Haberichter</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balistreri</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christopherson</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morateck</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gavazova</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bellissimo</surname>
                    <given-names>DB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manco-Johnson</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gill</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montgomery</surname>
                    <given-names>RR</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival.</article-title>
                <source>Blood</source>
                <volume>108</volume>
                <fpage>3344</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">16835381</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.haberichter.2008.4979">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Haberichter</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castaman</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Budde</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peake</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goodeve</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodeghiero</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Federici</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Batlle</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazurier</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goudemand</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eikenboom</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneppenheim</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ingerslev</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vorlova</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Habart</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmberg</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lethagen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hill</surname>
                    <given-names>FG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montgomery</surname>
                    <given-names>RR</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).</article-title>
                <source>Blood</source>
                <volume>111</volume>
                <fpage>4979</fpage>
                <lpage>85</lpage>
                <pub-id pub-id-type="pmid">18344424</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.hamilton.2011.501">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hamilton</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozelo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leggo</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Notley</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frontroth</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angelillo-Scherrer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baghaei</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Enayat</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Favaloro</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lillicrap</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Othman</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Frequency of platelet type versus type 2B von Willebrand disease. An international registry-based study.</article-title>
                <source>J Thromb Haemost</source>
                <volume>105</volume>
                <fpage>501</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">21301777</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.hashemi_soteh.2007.550">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hashemi Soteh</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peake</surname>
                    <given-names>IR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marsden</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anson</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Batlle</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fressinaud</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazurier</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goudemand</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eikenboom</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goodeve</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Mutational analysis of the von Willebrand factor gene in type 1 von Willebrand disease using conformation sensitive gel electrophoresis: a comparison of fluorescent and manual techniques.</article-title>
                <source>Haematologica</source>
                <volume>92</volume>
                <fpage>550</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">17488667</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.hassenpflug.2006.2339">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hassenpflug</surname>
                    <given-names>WA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Budde</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Obser</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angerhaus</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drewke</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneppenheim</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneppenheim</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis.</article-title>
                <source>Blood</source>
                <volume>107</volume>
                <fpage>2339</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">16322474</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF48">
              <mixed-citation publication-type="webpage">International Society on Thrombosis and Haemostasis. ISTH Scientific and Standardization Committee Bleeding Assessment Tool. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://c.ymcdn.com/sites/www.isth.org/resource/resmgr/ssc/isth-ssc_bleeding_assessment.pdf">online</ext-link>. 2011. Accessed 1-19-2016.</mixed-citation>
            </ref>
            <ref id="von-willebrand.REF.james.2007.1165">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>James</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jamison</surname>
                    <given-names>MG</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Bleeding events and other complications during pregnancy and childbirth in women with von Willebrand disease.</article-title>
                <source>J Thromb Haemost</source>
                <volume>5</volume>
                <fpage>1165</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">17403089</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.james.2009.12.e1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>James</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kouides</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abdul-Kadir</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edlund</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Federici</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halimeh</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamphuisen</surname>
                    <given-names>PW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Konkle</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mart&#x000ed;nez-Perez</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLintock</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peyvandi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winikoff</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel.</article-title>
                <source>Am J Obstet Gynecol.</source>
                <volume>201</volume>
                <fpage>12.e1</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">19481722</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.james.2006.546">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>James</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lillicrap</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Genetic testing for von Willebrand disease: the Canadian experience.</article-title>
                <source>Semin Thromb Hemost</source>
                <volume>32</volume>
                <fpage>546</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">16862529</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.james.2007a.145">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>James</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Notley</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hegadorn</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leggo</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tuttle</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tinlin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andrews</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Labelle</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chirinian</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O&#x02019;Brien</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Othman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rivard</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rapson</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hough</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lillicrap</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2007a</year>
                <article-title>The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study.</article-title>
                <source>Blood</source>
                <volume>109</volume>
                <fpage>145</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">17190853</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.james.2007b.1914">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>James</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Notley</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hegadorn</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poon</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walker</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rapson</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lillicrap</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2007b</year>
                <article-title>Challenges in defining type 2M von Willebrand disease: results from a Canadian cohort study.</article-title>
                <source>J Thromb Haemost</source>
                <volume>5</volume>
                <fpage>1914</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">17596142</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.jenkins.2006.1836">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jenkins</surname>
                    <given-names>PV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O&#x02019;Donnell</surname>
                    <given-names>JS</given-names>
                  </name>
                </person-group>
                <article-title>ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?</article-title>
                <source>Transfusion.</source>
                <year>2006</year>
                <volume>46</volume>
                <fpage>1836</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">17002642</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.johnsen.2013.590">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Johnsen</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Auer</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morrison</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jiao</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wei</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haessler</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fox</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGee</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carlson</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boerwinkle</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kooperberg</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nickerson</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rich</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Green</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peters</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cushman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reiner</surname>
                    <given-names>AP</given-names>
                  </name>
                  <collab>NHLBI Exome Sequencing Project</collab>
                </person-group>
                <year>2013</year>
                <article-title>Common and rare von Willebrand factor (VWF) coding variants, VWF levels, and factor VIII levels in African Americans: the NHLBI Exome Sequencing Project.</article-title>
                <source>Blood.</source>
                <volume>122</volume>
                <fpage>590</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">23690449</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.kadir.2006.605">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kadir</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chi</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Women and von Willebrand disease: controversies in diagnosis and management.</article-title>
                <source>Semin Thromb Hemost</source>
                <volume>32</volume>
                <fpage>605</fpage>
                <lpage>15</lpage>
                <pub-id pub-id-type="pmid">16977570</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.keeling.2012.e33">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Keeling</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beavis</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marr</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sukhu</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bignell</surname>
                    <given-names>P.</given-names>
                  </name>
                </person-group>
                <article-title>A family with type 2M VWD with normal VWF:RCo but reduced VWF:CB and a M1761K mutation in the A3 domain.</article-title>
                <source>Haemophilia.</source>
                <year>2012</year>
                <month>Jan</month>
                <volume>18</volume>
                <issue>1</issue>
                <fpage>e33</fpage>
                <pub-id pub-id-type="pmid">22004444</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.keeney.2008.1099">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Keeney</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowen</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cumming</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Enayat</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goodeve</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hill</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>The molecular analysis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors&#x02019; Organisation Haemophilia Genetics Laboratory Network.</article-title>
                <source>Haemophilia</source>
                <volume>14</volume>
                <fpage>1099</fpage>
                <lpage>111</lpage>
                <pub-id pub-id-type="pmid">18637846</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.leissinger.2014.158">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Leissinger</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carcao</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gill</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Journeycake</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Singleton</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valentino</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <article-title>Desmopressin (DDAVP) in the management of patients with congenital bleeding disorders.</article-title>
                <source>Haemophilia.</source>
                <year>2014</year>
                <volume>20</volume>
                <fpage>158</fpage>
                <lpage>67</lpage>
                <pub-id pub-id-type="pmid">23937614</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.mannucci.2013.648">
              <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Mannucci</surname><given-names>PM</given-names></name><name name-style="western"><surname>Kempton</surname><given-names>C</given-names></name><name name-style="western"><surname>Millar</surname><given-names>C</given-names></name><name name-style="western"><surname>Romond</surname><given-names>E</given-names></name><name name-style="western"><surname>Shapiro</surname><given-names>A</given-names></name><name name-style="western"><surname>Birschmann</surname><given-names>I</given-names></name><name name-style="western"><surname>Ragni</surname><given-names>MV</given-names></name><name name-style="western"><surname>Gill</surname><given-names>JC</given-names></name><name name-style="western"><surname>Yee</surname><given-names>TT</given-names></name><name name-style="western"><surname>Klamroth</surname><given-names>R</given-names></name><name name-style="western"><surname>Wong</surname><given-names>WY</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>M</given-names></name><name name-style="western"><surname>Engl</surname><given-names>W</given-names></name><name name-style="western"><surname>Turecek</surname><given-names>PL</given-names></name><name name-style="western"><surname>Suiter</surname><given-names>TM</given-names></name><name name-style="western"><surname>Ewenstein</surname><given-names>BM</given-names></name></person-group>rVWF Ad Hoc Study Group<year>2013</year><article-title>Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.</article-title><source>Blood.</source><volume>122</volume><fpage>648</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">23777763</pub-id></mixed-citation>
            </ref>
            <ref id="von-willebrand.REF.mazurier.2005.350">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mazurier</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hilbert</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Type 2N von Willebrand disease.</article-title>
                <source>Curr Hematol Rep</source>
                <volume>4</volume>
                <fpage>350</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16131435</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.mazurier.2001.712">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mazurier</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodeghiero</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Recommended abbreviations for von Willebrand factor and its activities.</article-title>
                <source>Thromb Haemost</source>
                <volume>86</volume>
                <fpage>712</fpage>
                <pub-id pub-id-type="pmid">11522027</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.metjian.2009.918">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Metjian</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sood</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cuker</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peterson</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soucie</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Konkle</surname>
                    <given-names>BA</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease.</article-title>
                <source>Haemophilia</source>
                <volume>15</volume>
                <fpage>918</fpage>
                <lpage>25</lpage>
                <pub-id pub-id-type="pmid">19473418</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.millar.2008.916">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Millar</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riddell</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Starke</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mackie</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowen</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jenkins</surname>
                    <given-names>PV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Mourik</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations.</article-title>
                <source>Thromb Haemost</source>
                <volume>99</volume>
                <fpage>916</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">18449422</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.nichols.2008.171">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nichols</surname>
                    <given-names>WL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hultin</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>James</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manco-Johnson</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montgomery</surname>
                    <given-names>RR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ortel</surname>
                    <given-names>TL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rick</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sadler</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weinstein</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yawn</surname>
                    <given-names>BP</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).</article-title>
                <source>Haemophilia</source>
                <volume>14</volume>
                <fpage>171</fpage>
                <lpage>232</lpage>
                <pub-id pub-id-type="pmid">18315614</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.o_brien.2003.549">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>O&#x02019;Brien</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>James</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Othman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berber</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cameron</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Notley</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hegadorn</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sutherland</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hough</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rivard</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O&#x02019;Shaunessey</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lillicrap</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease.</article-title>
                <source>Blood</source>
                <volume>102</volume>
                <fpage>549</fpage>
                <lpage>57</lpage>
                <pub-id pub-id-type="pmid">12649144</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.othman.2010.3645">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Othman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chirinian</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Notley</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hickson</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hampshire</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buckley</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waddington</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parker</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baker</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>James</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lillicrap</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease.</article-title>
                <source>Blood.</source>
                <volume>116</volume>
                <fpage>3645</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">20696945</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.othman.2005.4330">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Othman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Notley</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lavender</surname>
                    <given-names>FL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byrne</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lillicrap</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O&#x02019;Shaughnessy</surname>
                    <given-names>DF</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Identification and functional characterization of a novel 27-bp deletion in the macroglycopeptide-coding region of the GPIBA gene resulting in platelet-type von Willebrand disease.</article-title>
                <source>Blood</source>
                <volume>105</volume>
                <fpage>4330</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15705799</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.rodeghiero.2010.2063">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rodeghiero</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tosetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abshire</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arnold</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coller</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>James</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neunert</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lillicrap</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders.</article-title>
                <source>J Thromb Haemost</source>
                <volume>8</volume>
                <fpage>2063</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">20626619</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.sadler.1998.395">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sadler</surname>
                    <given-names>JE</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Biochemistry and genetics of von Willebrand factor.</article-title>
                <source>Ann Rev Biochem</source>
                <volume>67</volume>
                <fpage>395</fpage>
                <lpage>424</lpage>
                <pub-id pub-id-type="pmid">9759493</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.sadler.2006.2103">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sadler</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Budde</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eikenboom</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Favaloro</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hill</surname>
                    <given-names>FG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmberg</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ingerslev</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lillicrap</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mannucci</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazurier</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nichols</surname>
                    <given-names>WL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishino</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peake</surname>
                    <given-names>IR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodeghiero</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneppenheim</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruggeri</surname>
                    <given-names>ZM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Srivastava</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montgomery</surname>
                    <given-names>RR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Federici</surname>
                    <given-names>AB</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.</article-title>
                <source>J Thromb Haemost.</source>
                <volume>4</volume>
                <fpage>2103</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">16889557</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.schneppenheim.2011.209">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schneppenheim</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Budde</surname>
                    <given-names>U</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>von Willebrand factor: the complex molecular genetics of a multidomain and multifunctional protein.</article-title>
                <source>J Thromb Haemost.</source>
                <volume>9</volume>
                <fpage>209</fpage>
                <lpage>15</lpage>
                <pub-id pub-id-type="pmid">21781257</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.schneppenheim.2011">
              <mixed-citation publication-type="other">Schneppenheim R, Ledford-Kraemer M, Lavergne J-M, Marschalek R, Montgomery R, Obser T, Oyen F, Sadler JE, Schneppenheim S, Budde U. Identification of the elusive mutation causing the historical von Willebrand disease type IIC miami. J Thromb Haemost. 2011;9 Suppl 1:P-WE-461.</mixed-citation>
            </ref>
            <ref id="von-willebrand.REF.schneppenheim.2010.4894">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schneppenheim</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michiels</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Obser</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oyen</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pieconka</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneppenheim</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Will</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zieger</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Budde</surname>
                    <given-names>U</given-names>
                  </name>
                </person-group>
                <article-title>A cluster of mutations in the D3 domain of von Willebrand factor correlates with a distinct subgroup of von Willebrand disease: type 2A/IIE.</article-title>
                <source>Blood.</source>
                <year>2010</year>
                <volume>115</volume>
                <fpage>4894</fpage>
                <lpage>901</lpage>
                <pub-id pub-id-type="pmid">20351307</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.solimando.2012.870">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Solimando</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baronciani</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>La Marca</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cozzi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Asselta</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Canciani</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Federici</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peyvandi</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Molecular characterization, recombinant protein expression, and mRNA analysis of type 3 von Willebrand disease: Studies of an Italian cohort of 10 patients.</article-title>
                <source>Am J Hematol.</source>
                <volume>87</volume>
                <fpage>870</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">22674667</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.sucker.2009.177">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sucker</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michiels</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zotz</surname>
                    <given-names>RB</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Causes, etiology and diagnosis of acquired von Willebrand disease: a prospective diagnostic workup to establish the most effective therapeutic strategies.</article-title>
                <source>Acta Haematol.</source>
                <volume>121</volume>
                <fpage>177</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">19506364</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.sutherland.2009.1091">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sutherland</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cumming</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bolton-Maggs</surname>
                    <given-names>PH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowen</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>PW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hay</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Will</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keeney</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>A novel deletion mutation is recurrent in von Willebrand disease types 1 and 3.</article-title>
                <source>Blood.</source>
                <volume>114</volume>
                <fpage>1091</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">19372260</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.tosetto.2011.1143">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tosetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castaman</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plug</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodeghiero</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eikenboom</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation.</article-title>
                <source>J Thromb Haemost.</source>
                <volume>9</volume>
                <fpage>1143</fpage>
                <lpage>48</lpage>
                <pub-id pub-id-type="pmid">21435168</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.tosetto.2006.766">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tosetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodeghiero</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castaman</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goodeve</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Federici</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Batlle</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fressinaud</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazurier</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goudemand</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eikenboom</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneppenheim</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Budde</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ingerslev</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vorlova</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Habart</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmberg</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lethagen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hill</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peake</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD).</article-title>
                <source>J Thromb Haemost</source>
                <volume>4</volume>
                <fpage>766</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">16634745</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.turacek.2010.510">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Turacek</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schrenk</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rottensteiner</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Varadi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bevers</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lenting</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ilk</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sleytr</surname>
                    <given-names>UB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ehrlich</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shwartz</surname>
                    <given-names>HP</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Structure and function of a recombinant von Willebrand factor drug candidate.</article-title>
                <source>Semin Thromb Hemost</source>
                <volume>36</volume>
                <fpage>510</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">20635317</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.varughese.2007.730">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Varughese</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>AJ</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Experience with epidural anaesthesia in pregnant women with von Willebrand disease.</article-title>
                <source>Haemophilia</source>
                <volume>13</volume>
                <fpage>730</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">17973849</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.valentijn.2013.581">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Valentijn</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eikenboom</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Weibel-Palade bodies: a window to von Willebrand disease.</article-title>
                <source>J Thromb Haemost.</source>
                <volume>11</volume>
                <fpage>581</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">23398618</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.veyradier.2011.944">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Veyradier</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caron</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ternisien</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolf</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trossaert</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fressinaud</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goudemand</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Validation of the first commercial ELISA for type 2N von Willebrand&#x02019;s disease diagnosis.</article-title>
                <source>Haemophilia.</source>
                <volume>17</volume>
                <fpage>944</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">21371195</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.vidal.2005.976">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vidal</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Julia</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Altisent</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Puig</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallardo</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Von Willebrand gene tracking by single-tube automated fluorescent analysis of four short tandem repeat polymorphisms.</article-title>
                <source>Thromb Haemost</source>
                <volume>93</volume>
                <fpage>976</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">15886817</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.woods.2014.151">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Woods</surname>
                    <given-names>AI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanchez-Luceros</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bermejo</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paiva</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alberto</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grosso</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kempfer</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lazzari</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <article-title>Identification of p.W246L as a novel mutation in the GP1BA gene responsible for platelet-type von Willebrand disease.</article-title>
                <source>Semin Thromb Hemost.</source>
                <year>2014</year>
                <volume>40</volume>
                <fpage>151</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">24474090</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.yadegari.2011.1083">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yadegari</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Driesen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hass</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Budde</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pavlova</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oldenburg</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Large deletions identified in patients with von Willebrand disease using multiple ligation-dependent probe amplification.</article-title>
                <source>J Thromb Haemost.</source>
                <volume>9</volume>
                <fpage>1083</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">21410641</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.yadegari.2012.662">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yadegari</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Driesen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pavlova</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biswas</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hertfelder</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oldenburg</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Mutation distribution in the von Willebrand factor gene related to the different von Willebrand disease (VWD) types in a cohort of VWD patients.</article-title>
                <source>Thromb Haemost.</source>
                <volume>108</volume>
                <fpage>662</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">22871923</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.zhou.2012.449">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>YF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>ET</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhu</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lu</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walz</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Springer</surname>
                    <given-names>TA</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Sequence and structure relationships within von Willebrand factor.</article-title>
                <source>Blood.</source>
                <volume>120</volume>
                <fpage>449</fpage>
                <lpage>58</lpage>
                <pub-id pub-id-type="pmid">22490677</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF.zhou.2014.e84810">
              <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yu</surname><given-names>F</given-names></name><name name-style="western"><surname>Buchanan</surname><given-names>A</given-names></name><name name-style="western"><surname>Fu</surname><given-names>F</given-names></name><name name-style="western"><surname>Campos</surname><given-names>M</given-names></name><name name-style="western"><surname>Wu</surname><given-names>KK</given-names></name><name name-style="western"><surname>Lloyd</surname><given-names>E</given-names></name></person-group>Chambless, ARF, Eric Boerwinkle, Dong JF<year>2014</year><article-title>Possible Race and Gender Divergence in Association of Genetic Variations with Plasma von Willebrand Factor: A Study of ARIC and 1000 Genome Cohorts.</article-title><source>PloS One.</source><volume>9</volume><fpage>e84810</fpage><pub-id pub-id-type="pmid">24465435</pub-id></mixed-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="von-willebrand.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="von-willebrand.Suggested_Reading.reflist0">
            <ref id="von-willebrand.REF.federici.2007.346">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Federici</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mannucci</surname>
                    <given-names>PM</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Management of inherited von Willebrand disease in 2007.</article-title>
                <source>Ann Med</source>
                <volume>39</volume>
                <fpage>346</fpage>
                <lpage>58</lpage>
                <pub-id pub-id-type="pmid">17701477</pub-id>
              </element-citation>
            </ref>
            <ref id="von-willebrand.REF91">
              <mixed-citation publication-type="webpage">ISTH-VWF-SSC International Society on Thrombosis and Haemostasis Scientific and Standardization Committee VWF Information Homepage. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.vwf.group.shef.ac.uk/">online</ext-link>. Accessed 1-19-16.</mixed-citation>
            </ref>
            <ref id="von-willebrand.REF.james.2006.136">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>James</surname>
                    <given-names>AH</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Von Willebrand disease.</article-title>
                <source>Obstet Gynecol Surv</source>
                <volume>61</volume>
                <fpage>136</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">16433937</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="von-willebrand.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="von-willebrand.Author_Notes">
          <title>Author Notes</title>
          <p>Prof. Goodeve&#x02019;s <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.sheffield.ac.uk/iicd/profiles/goodeve">Web page</ext-link></p>
          <p>Dr. James&#x02019;s <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinlabs.path.queensu.ca/queens/labs/lillicrap/paula.htm">Web page</ext-link></p>
        </sec>
        <sec id="von-willebrand.Acknowledgments">
          <title>Acknowledgments</title>
          <p>The authors would like to thank Professor David Lillicrap, Kingston, Canada, for critical reading of the review and Dr Mackenzie Bowman, Kingston Canada for preparation of the figure.</p>
        </sec>
        <sec id="von-willebrand.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>24 July 2014 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>13 October 2011 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>26 October 2010 (cd) Revision: deletion/duplication analysis available clinically</p>
            </list-item>
            <list-item>
              <p>4 June 2009 (et) Review posted live</p>
            </list-item>
            <list-item>
              <p>4 December 2008 (ag) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="von-willebrand.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>VWF protein structure [adapted from <xref ref-type="bibr" rid="von-willebrand.REF.zhou.2012.449">Zhou et al 2012</xref>] and location of <italic toggle="yes">VWF</italic> pathogenic variants by VWD type. Bold horizontal lines indicate the approximate position of exons where pathogenic variants are most prevalent; thinner lines indicate exons with variants of lower frequency. Pathogenic variants that result in type 2 VWD affect VWF function and cluster in domains primarily disrupted by missense variants.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="von-willebrand-Image001" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
